

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

CROPHARMA

Table 1 Page 1.....	SCREENER 1020 WOULD YOU DESCRIBE YOUR ROLE IN YOUR ORGANIZATION AS EITHER THAT OF A PRINCIPAL INVESTIGATOR OR STUDY COORDINATOR TOTAL
Table 2 Page 2.....	SCREENER 1030 IN THE PAST 24 MONTHS, WITH WHICH CROS (CONTRACT RESEARCH ORGANIZATIONS) HAVE YOU CONDUCTED CLINICAL RESEARCH FIRST MENTION TOTAL
Table 3 Page 3.....	SCREENER 1030 IN THE PAST 24 MONTHS, WITH WHICH CROS (CONTRACT RESEARCH ORGANIZATIONS) HAVE YOU CONDUCTED CLINICAL RESEARCH TOTAL MENTIONS TOTAL
Table 4 Page 4.....	QUESTION 2000 MEAN SUMMARY IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS TOTAL
Table 5 Page 5.....	QUESTION 2000 TOP BOX (5) ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS TOTAL
Table 6 Page 6.....	QUESTION 2000 TOP 2 BOX (4 5) ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS TOTAL
Table 7 Page 7.....	QUESTION 2000A IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS The contract research organization's CRAs TOTAL
Table 8 Page 8.....	QUESTION 2000B IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS The CRO's query process TOTAL
Table 9 Page 9.....	QUESTION 2000C IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS The CRO's grant payment process TOTAL
Table 10 Page 10.....	QUESTION 2010 MEAN SUMMARY CRA RATINGS CROPHARMA FILTER: RATED CROPHARMA
Table 11 Page 11.....	QUESTION 2010 TOP BOX (5) CRA RATINGS CROPHARMA FILTER: RATED CROPHARMA
Table 12 Page 13.....	QUESTION 2010 TOP 2 BOX (4 5) CRA RATINGS CROPHARMA FILTER: RATED CROPHARMA
Table 13 Page 15.....	QUESTION 2010 CROPHARMA RATING Having low monitor turnover FILTER: RATED CROPHARMA

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 14	Page 16	QUESTION 2010 CROPHARMA RATING Managing monitor turnover FILTER: RATED CROPHARMA
Table 15	Page 17	QUESTION 2010 CROPHARMA RATING Support for facilitating regulatory approvals FILTER: RATED CROPHARMA
Table 16	Page 18	QUESTION 2010 CROPHARMA RATING Maintaining the availability of clinical trial supplies FILTER: RATED CROPHARMA
Table 17	Page 19	QUESTION 2010 CROPHARMA RATING Being innovative in their support of patient recruitment FILTER: RATED CROPHARMA
Table 18	Page 20	QUESTION 2010 CROPHARMA RATING Their ability to train site staff in study protocol FILTER: RATED CROPHARMA
Table 19	Page 21	QUESTION 2010 CROPHARMA RATING Their ability to liaise with the study sponsor FILTER: RATED CROPHARMA
Table 20	Page 22	QUESTION 2010 CROPHARMA RATING The quality of their CRAs over all FILTER: RATED CROPHARMA
Table 21	Page 23	QUESTION 2010 CROPHARMA RATING Providing well designed case report forms FILTER: RATED CROPHARMA
Table 22	Page 24	QUESTION 2010 CROPHARMA RATING Having an efficient data query handling process FILTER: RATED CROPHARMA
Table 23	Page 25	QUESTION 2010 CROPHARMA RATING Providing fair grant payment amounts FILTER: RATED CROPHARMA
Table 24	Page 26	QUESTION 2010 CROPHARMA RATING Providing reasonable grant payment schedules FILTER: RATED CROPHARMA
Table 25	Page 27	QUESTION 2010 CROPHARMA RATING Providing prompt grant payments FILTER: RATED CROPHARMA
Table 26	Page 28	QUESTION 2010 CROPHARMA RATING Their grant payment process over all FILTER: RATED CROPHARMA

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 27	Page 29	QUESTION 2010 MEAN SUMMARY CRA RATINGS BETA THERAPEUTIC FILTER: RATED BETA THERAPEUTIC
Table 28	Page 30	QUESTION 2010 TOP BOX (5) CRA RATINGS BETA THERAPEUTIC FILTER: RATED BETA THERAPEUTIC
Table 29	Page 32	QUESTION 2010 TOP 2 BOX (4 5) CRA RATINGS BETA THERAPEUTIC FILTER: RATED BETA THERAPEUTIC
Table 30	Page 34	QUESTION 2010 BETA THERAPEUTIC RATING Having low monitor turnover FILTER: RATED BETA THERAPEUTIC
Table 31	Page 35	QUESTION 2010 BETA THERAPEUTIC RATING Managing monitor turnover FILTER: RATED BETA THERAPEUTIC
Table 32	Page 36	QUESTION 2010 BETA THERAPEUTIC RATING Support for facilitating regulatory approvals FILTER: RATED BETA THERAPEUTIC
Table 33	Page 37	QUESTION 2010 BETA THERAPEUTIC RATING Maintaining the availability of clinical trial supplies FILTER: RATED BETA THERAPEUTIC
Table 34	Page 38	QUESTION 2010 BETA THERAPEUTIC RATING Being innovative in their support of patient recruitment FILTER: RATED BETA THERAPEUTIC
Table 35	Page 39	QUESTION 2010 BETA THERAPEUTIC RATING Their ability to train site staff in study protocol FILTER: RATED BETA THERAPEUTIC
Table 36	Page 40	QUESTION 2010 BETA THERAPEUTIC RATING Their ability to liaise with the study sponsor FILTER: RATED BETA THERAPEUTIC
Table 37	Page 41	QUESTION 2010 BETA THERAPEUTIC RATING The quality of their CRAs over all FILTER: RATED BETA THERAPEUTIC
Table 38	Page 42	QUESTION 2010 BETA THERAPEUTIC RATING Providing well designed case report forms FILTER: RATED BETA THERAPEUTIC
Table 39	Page 43	QUESTION 2010 BETA THERAPEUTIC RATING Having an efficient data query handling process FILTER: RATED BETA THERAPEUTIC

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 40	Page 44	QUESTION 2010 BETA THERAPEUTIC RATING Providing fair grant payment amounts FILTER: RATED BETA THERAPEUTIC
Table 41	Page 45	QUESTION 2010 BETA THERAPEUTIC RATING Providing reasonable grant payment schedules FILTER: RATED BETA THERAPEUTIC
Table 42	Page 46	QUESTION 2010 BETA THERAPEUTIC RATING Providing prompt grant payments FILTER: RATED BETA THERAPEUTIC
Table 43	Page 47	QUESTION 2010 BETA THERAPEUTIC RATING Their grant payment process over all FILTER: RATED BETA THERAPEUTIC
Table 44	Page 48	QUESTION 2010 MEAN SUMMARY CRA RATINGS MATRIX, INC. FILTER: RATED MATRIX, INC.
Table 45	Page 49	QUESTION 2010 TOP BOX (5) CRA RATINGS MATRIX, INC. FILTER: RATED MATRIX, INC.
Table 46	Page 51	QUESTION 2010 TOP 2 BOX (4 5) CRA RATINGS MATRIX, INC. FILTER: RATED MATRIX, INC.
Table 47	Page 53	QUESTION 2010 MATRIX, INC. RATING Having low monitor turnover FILTER: RATED MATRIX, INC.
Table 48	Page 54	QUESTION 2010 MATRIX, INC. RATING Managing monitor turnover FILTER: RATED MATRIX, INC.
Table 49	Page 55	QUESTION 2010 MATRIX, INC. RATING Support for facilitating regulatory approvals FILTER: RATED MATRIX, INC.
Table 50	Page 56	QUESTION 2010 MATRIX, INC. RATING Maintaining the availability of clinical trial supplies FILTER: RATED MATRIX, INC.
Table 51	Page 57	QUESTION 2010 MATRIX, INC. RATING Being innovative in their support of patient recruitment FILTER: RATED MATRIX, INC.
Table 52	Page 58	QUESTION 2010 MATRIX, INC. RATING Their ability to train site staff in study protocol FILTER: RATED MATRIX, INC.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 53 Page 59.....QUESTION 2010
MATRIX, INC. RATING
Their ability to liaise with the study sponsor
FILTER: RATED MATRIX, INC.

Table 54 Page 60.....QUESTION 2010
MATRIX, INC. RATING
The quality of their CRAs over all
FILTER: RATED MATRIX, INC.

Table 55 Page 61.....QUESTION 2010
MATRIX, INC. RATING
Providing well designed case report forms
FILTER: RATED MATRIX, INC.

Table 56 Page 62.....QUESTION 2010
MATRIX, INC. RATING
Having an efficient data query handling process
FILTER: RATED MATRIX, INC.

Table 57 Page 63.....QUESTION 2010
MATRIX, INC. RATING
Providing fair grant payment amounts
FILTER: RATED MATRIX, INC.

Table 58 Page 64.....QUESTION 2010
MATRIX, INC. RATING
Providing reasonable grant payment schedules
FILTER: RATED MATRIX, INC.

Table 59 Page 65.....QUESTION 2010
MATRIX, INC. RATING
Providing prompt grant payments
FILTER: RATED MATRIX, INC.

Table 60 Page 66.....QUESTION 2010
MATRIX, INC. RATING
Their grant payment process over all
FILTER: RATED MATRIX, INC.

Table 61 Page 67.....QUESTION 2010
MEAN SUMMARY CRA RATINGS
PHARMA FOCUS
FILTER: RATED PHARMA FOCUS

Table 62 Page 68.....QUESTION 2010
TOP BOX (5) CRA RATINGS
PHARMA FOCUS
FILTER: RATED PHARMA FOCUS

Table 63 Page 70.....QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
PHARMA FOCUS
FILTER: RATED PHARMA FOCUS

Table 64 Page 72.....QUESTION 2010
PHARMA FOCUS RATING
Having low monitor turnover
FILTER: RATED PHARMA FOCUS

Table 65 Page 73.....QUESTION 2010
PHARMA FOCUS RATING
Managing monitor turnover
FILTER: RATED PHARMA FOCUS

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 66	Page 74	QUESTION 2010 PHARMA FOCUS RATING Support for facilitating regulatory approvals FILTER: RATED PHARMA FOCUS
Table 67	Page 75	QUESTION 2010 PHARMA FOCUS RATING Maintaining the availability of clinical trial supplies FILTER: RATED PHARMA FOCUS
Table 68	Page 76	QUESTION 2010 PHARMA FOCUS RATING Being innovative in their support of patient recruitment FILTER: RATED PHARMA FOCUS
Table 69	Page 77	QUESTION 2010 PHARMA FOCUS RATING Their ability to train site staff in study protocol FILTER: RATED PHARMA FOCUS
Table 70	Page 78	QUESTION 2010 PHARMA FOCUS RATING Their ability to liaise with the study sponsor FILTER: RATED PHARMA FOCUS
Table 71	Page 79	QUESTION 2010 PHARMA FOCUS RATING The quality of their CRAs over all FILTER: RATED PHARMA FOCUS
Table 72	Page 80	QUESTION 2010 PHARMA FOCUS RATING Providing well designed case report forms FILTER: RATED PHARMA FOCUS
Table 73	Page 81	QUESTION 2010 PHARMA FOCUS RATING Having an efficient data query handling process FILTER: RATED PHARMA FOCUS
Table 74	Page 82	QUESTION 2010 PHARMA FOCUS RATING Providing fair grant payment amounts FILTER: RATED PHARMA FOCUS
Table 75	Page 83	QUESTION 2010 PHARMA FOCUS RATING Providing reasonable grant payment schedules FILTER: RATED PHARMA FOCUS
Table 76	Page 84	QUESTION 2010 PHARMA FOCUS RATING Providing prompt grant payments FILTER: RATED PHARMA FOCUS
Table 77	Page 85	QUESTION 2010 PHARMA FOCUS RATING Their grant payment process over all FILTER: RATED PHARMA FOCUS
Table 78	Page 86	QUESTION 2020 HOW MANY YEARS OF EXPERIENCE DO YOU HAVE CONDUCTING CLINICAL TRIALS TOTAL
Table 79	Page 87	QUESTION 2030 HOW MANY CLINICAL TRIALS HAVE YOU WORKED ON IN THE LAST 24 MONTHS TOTAL

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

TABLE OF CONTENTS

Table 80	Page 88	QUESTION 2040 WITH WHICH CRO DO YOU MOST PREFER TO WORK TOTAL
Table 81	Page 89	QUESTION 2050 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE MOST? FILTER: HAVE A PREFERRED CRA
Table 82	Page 90	QUESTION 2050 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE MOST? FILTER: PREFER CROPHARMA
Table 83	Page 91	QUESTION 2050 WITH WHICH CRO DO YOU LEAST PREFER TO WORK TOTAL
Table 84	Page 92	QUESTION 2050 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE LEAST? FILTER: HAVE A LEAST PREFERRED CRA
Table 85	Page 93	QUESTION 2050 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE LEAST? FILTER: CROPHARMA LEAST PREFERRED
Table 86	Page 94	QUESTION 2080 OVER ALL, HOW WOULD YOU RATE THE QUALITY OF YOUR WORKING RELATIONSHIP WITH CROPHARMA TOTAL
Table 87	Page 95	QUESTION 2090 HOW LIKELY WOULD YOU BE TO RECOMMEND CROPHARMA TOTAL

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

SCREENER 1020
 WOULD YOU DESCRIBE YOUR ROLE IN YOUR ORGANIZATION AS EITHER THAT OF A PRINCIPAL
 INVESTIGATOR OR STUDY COORDINATOR

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186	40	37	61	24	24
	100.0	100.0	100.0	100.0	100.0	100.0
Principal investigator	114	21	29	32	8	24
	61.3	52.5	78.4	52.5	33.3	100.0
			BDE	e		BCDE
Study coordinator	72	19	8	29	16	-
	38.7	47.5	21.6	47.5	66.7	
		C		C	Cd	
CHI-SQUARE	<-----30.926----->					
SIGNIFICANCE	100.0%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

SCREENER 1030
 IN THE PAST 24 MONTHS, WITH WHICH CROS (CONTRACT RESEARCH ORGANIZATIONS) HAVE
 YOU CONDUCTED CLINICAL RESEARCH
 FIRST MENTION

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186	40	37	61	24	24
	100.0	100.0	100.0	100.0	100.0	100.0
CROPHARMA	121	30	27	29	18	17
	65.1	75.0	73.0	47.5	75.0	70.8
		D	D		D	D
BETA THERAPEUTIC	26	5	4	12	2	3
	14.0	12.5	10.8	19.7	8.3	12.5
MATRIX, INC.	11	2	2	1	3	3
	5.9	5.0	5.4	1.6	12.5	12.5
PHARMA FOCUS	8	3	3	1	1	-
	4.3	7.5	8.1	1.6	4.2	
Other	20	-	1	18	-	1
	10.8		2.7	29.5		4.2
				CF		
CHI-SQUARE SIGNIFICANCE	<-----46.407----->					
	100.0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

SCREENER 1030
 IN THE PAST 24 MONTHS, WITH WHICH CROS (CONTRACT RESEARCH ORGANIZATIONS) HAVE
 YOU CONDUCTED CLINICAL RESEARCH
 TOTAL MENTIONS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
CROPHARMA	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
BETA THERAPEUTIC	53 28.5	10 25.0	9 24.3	24 39.3 E	4 16.7	6 25.0
MATRIX, INC.	38 20.4	6 15.0	10 27.0	10 16.4	9 37.5 BdF	3 12.5
PHARMA FOCUS	17 9.1	10 25.0 DE	5 13.5 D	1 1.6	1 4.2	-
Other	20 10.8	-	1 2.7	18 29.5 CF	-	1 4.2
CHI-SQUARE SIGNIFICANCE	<-----55.213-----> 100.0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are
 significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2000
 MEAN SUMMARY IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186	40	37	61	24	24
	100.0	100.0	100.0	100.0	100.0	100.0
The contract research organization's CRAs	4.2	4.4 A	4.2 BA	4.0 B	4.5 A	4.3 BA
The CRO's query process	4.0	4.0 B	4.1 BA	3.6 C	4.5 A	4.0 BA
The CRO's grant payment process	3.7	3.9 A	3.4 B	3.3 B	4.1 A	4.3 A
CHI-SQUARE SIGNIFICANCE	<----- .072 -----> .0%					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2000
 TOP BOX (5) ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
The contract research organization's CRAs	84 45.2	21 52.5 D	15 40.5	18 29.5	17 70.8 CD	13 54.2 D
The CRO's query process	62 33.3	16 40.0 D	11 29.7 d	9 14.8	18 75.0 BCDF	8 33.3 d
The CRO's grant payment process	46 24.7	12 30.0 CD	4 10.8	8 13.1	12 50.0 CD	10 41.7 CD
CHI-SQUARE SIGNIFICANCE	<-----5.344-----> 28.0%					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2000
 TOP 2 BOX (4 5) ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
The contract research organization's CRAs	149 80.1	35 87.5	29 78.4	48 78.7	20 83.3	17 70.8
The CRO's query process	125 67.2	28 70.0 D	29 78.4 D	31 50.8	20 83.3 D	17 70.8 d
The CRO's grant payment process	106 57.0	26 65.0 cD	17 45.9	25 41.0	17 70.8 CD	21 87.5 BCD
CHI-SQUARE SIGNIFICANCE	<-----7.272-----> 49.2%					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2000A
IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS
The contract research organization's CRAs

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186	40	37	61	24	24
	100.0	100.0	100.0	100.0	100.0	100.0
EXTREMELY/VERY IMPORTANT (4 5)	149	35	29	48	20	17
	80.1	87.5	78.4	78.7	83.3	70.8
Extremely important (5)	84	21	15	18	17	13
	45.2	52.5	40.5	29.5	70.8	54.2
		D			CD	D
Very important (4)	65	14	14	30	3	4
	34.9	35.0	37.8	49.2	12.5	16.7
		Ef	Ef	EF		
Three	27	3	7	9	4	4
	14.5	7.5	18.9	14.8	16.7	16.7
NOT/NOT AT ALL IMPORTANT	7	2	-	4	-	1
	3.8	5.0		6.6		4.2
Not important	5	2	-	3	-	-
	2.7	5.0		4.9		
Not at all important	2	-	-	1	-	1
	1.1			1.6		4.2
No answer	3	-	1	-	-	2
	1.6		2.7			8.3
CHI-SQUARE SIGNIFICANCE	<-----26.858----->					
	95.7%*					
MEAN	4.2	4.4	4.2	4.0	4.5	4.3
		A	BA	B	A	BA
STANDARD DEVIATION	0.9	0.8	0.8	0.9	0.8	1.1
STANDARD ERROR	0.1	0.1	0.1	0.1	0.2	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2000B
IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS
The CRO's query process

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
EXTREMELY/VERY IMPORTANT (4 5)	125 67.2	28 70.0	29 78.4	31 50.8	20 83.3	17 70.8
		D	D		D	d
Extremely important (5)	62 33.3	16 40.0	11 29.7	9 14.8	18 75.0	8 33.3
		D	d		BCDF	d
Very important (4)	63 33.9	12 30.0	18 48.6	22 36.1	2 8.3	9 37.5
		E	bE	E		E
Three	46 24.7	9 22.5	5 13.5	25 41.0	3 12.5	4 16.7
				BCEF		
NOT/NOT AT ALL IMPORTANT	11 5.9	3 7.5	2 5.4	4 6.6	1 4.2	1 4.2
Not important	10 5.4	3 7.5	2 5.4	4 6.6	1 4.2	-
Not at all important	1 0.5	-	-	-	-	1 4.2
No answer	4 2.2	-	1 2.7	1 1.6	-	2 8.3
CHI-SQUARE SIGNIFICANCE	<-----45.943-----> 100.0%*					
MEAN	4.0	4.0	4.1	3.6	4.5	4.0
		B	BA	C	A	BA
STANDARD DEVIATION	0.9	1.0	0.8	0.8	0.9	1.0
STANDARD ERROR	0.1	0.2	0.1	0.1	0.2	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2000C
IMPORTANCE ATTRIBUTES DESCRIBING CONTRACT RESEARCH ORGANIZATIONS
The CRO's grant payment process

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
EXTREMELY/VERY IMPORTANT (4 5)	106 57.0	26 65.0	17 45.9	25 41.0	17 70.8	21 87.5
		cD			CD	BCD
Extremely important (5)	46 24.7	12 30.0	4 10.8	8 13.1	12 50.0	10 41.7
		CD			CD	CD
Very important (4)	60 32.3	14 35.0	13 35.1	17 27.9	5 20.8	11 45.8
						e
Three	55 29.6	10 25.0	16 43.2	23 37.7	5 20.8	1 4.2
		F	beF	F	f	
NOT/NOT AT ALL IMPORTANT	22 11.8	3 7.5	4 10.8	12 19.7	2 8.3	1 4.2
				bF		
Not important	16 8.6	3 7.5	3 8.1	8 13.1	1 4.2	1 4.2
Not at all important	6 3.2	-	1 2.7	4 6.6	1 4.2	-
No answer	3 1.6	1 2.5	-	1 1.6	-	1 4.2
CHI-SQUARE SIGNIFICANCE	<-----35.314-----> 99.6%*					
MEAN	3.7	3.9	3.4	3.3	4.1	4.3
		A	B	B	A	A
STANDARD DEVIATION	1.0	0.9	0.9	1.1	1.1	0.8
STANDARD ERROR	0.1	0.2	0.1	0.1	0.2	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MEAN SUMMARY CRA RATINGS
 CROPHARMA

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166	40	36	44	24	22
	100.0	100.0	100.0	100.0	100.0	100.0
Support for facilitating regulatory approvals	4.1	4.0 CB	4.2 CBA	3.8 C	4.5 A	4.5 BA
Maintaining the availability of clinical trial supplies	4.0	3.8 B	3.6 B	3.9 B	4.7 A	4.7 A
The quality of their CRAs over all	4.0	3.7 B	3.8 B	3.9 B	4.3 A	4.5 A
Providing well designed case report forms	3.9	3.5 B	3.9 B	3.5 B	4.5 A	4.8 A
Having an efficient data query handling process	3.9	3.5 C	3.8 CB	3.9 B	4.1 BA	4.5 A
Their ability to liaise with the study sponsor	3.9	3.8 B	3.7 B	3.6 B	4.4 A	4.6 A
Managing monitor turnover	3.8	3.4 B	3.5 B	3.7 B	4.5 A	4.5 A
Their grant payment process over all	3.8	3.2 B	4.0 A	3.6 B	4.4 A	4.3 A
Having low monitor turnover	3.8	3.5 B	3.6 B	3.6 B	4.2 A	4.4 A
Providing fair grant payment amounts	3.8	3.4 D	3.9 CB	3.5 DC	4.1 BA	4.4 A
Their ability to train site staff in study protocol	3.7	3.6 B	3.6 B	3.5 B	4.2 A	4.3 A
Providing reasonable grant payment schedules	3.7	3.2 C	3.7 CB	3.5 C	4.0 BA	4.4 A
Providing prompt grant payments	3.6	3.3 C	3.8 CBA	3.4 CB	3.9 BA	4.2 A
Being innovative in their support of patient recruitment	3.1	2.9 B	2.8 B	2.8 B	4.2 A	3.4 BA
CHI-SQUARE SIGNIFICANCE	<-----9.597-----> .0%					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP BOX (5) CRA RATINGS
 CROPHARMA

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
Support for facilitating regulatory approvals	60 36.1	13 32.5	13 36.1	11 25.0	11 45.8 d	12 54.5 bD
Maintaining the availability of clinical trial supplies	53 31.9	6 15.0	5 13.9	8 18.2	17 70.8 BCD	17 77.3 BCD
Providing well designed case report forms	52 31.3	7 17.5	6 16.7	4 9.1	15 62.5 BCD	20 90.9 BCDE
Having low monitor turnover	50 30.1	10 25.0	8 22.2	7 15.9	13 54.2 BCD	12 54.5 BCD
The quality of their CRAs over all	44 26.5	10 25.0	4 11.1	7 15.9	12 50.0 BCD	11 50.0 BCD
Managing monitor turnover	44 26.5	6 15.0	4 11.1	9 20.5	13 54.2 BCD	12 54.5 BCD
Their ability to train site staff in study protocol	42 25.3	8 20.0	5 13.9	5 11.4	14 58.3 BCD	10 45.5 BCD
Having an efficient data query handling process	40 24.1	2 5.0	7 19.4 b	9 20.5 B	9 37.5 B	13 59.1 BCD
Providing prompt grant payments	38 22.9	6 15.0	6 16.7	4 9.1	9 37.5 BCD	13 59.1 BCD
Providing fair grant payment amounts	36 21.7	3 7.5	8 22.2 b	5 11.4	9 37.5 BD	11 50.0 BCD
Their ability to liaise with the study sponsor	36 21.7	7 17.5 c	2 5.6	4 9.1	12 50.0 BCD	11 50.0 BCD
Their grant payment process over all	35 21.1	2 5.0	8 22.2 B	6 13.6	9 37.5 BD	10 45.5 BCDComparison Groups: BCDEF

Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP BOX (5) CRA RATINGS
CROPHARMA

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Providing reasonable grant payment schedules	34 20.5	2 5.0	4 11.1	3 6.8	9 37.5 BCD	16 72.7 BCDE
Being innovative in their support of patient recruitment	20 12.0	4 10.0	1 2.8	-	12 50.0 BCF	3 13.6
CHI-SQUARE SIGNIFICANCE	<-----58.581-----> 75.3%					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are
significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
CROPHARMA

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166	40	36	44	24	22
	100.0	100.0	100.0	100.0	100.0	100.0
The quality of their CRAs over all	124	24	27	31	20	22
	74.7	60.0	75.0	70.5	83.3	100.0
					B	BCDE
Maintaining the availability of clinical trial supplies	117	28	16	33	19	21
	70.5	70.0	44.4	75.0	79.2	95.5
		C		C	C	BCDe
Providing well designed case report forms	115	22	28	23	21	21
	69.3	55.0	77.8	52.3	87.5	95.5
			BD		BD	BCD
Support for facilitating regulatory approvals	114	28	22	25	19	20
	68.7	70.0	61.1	56.8	79.2	90.9
					D	BCD
Having an efficient data query handling process	111	22	22	30	18	19
	66.9	55.0	61.1	68.2	75.0	86.4
					b	BCd
Managing monitor turnover	96	17	18	23	17	21
	57.8	42.5	50.0	52.3	70.8	95.5
					Bc	BCDE
Having low monitor turnover	96	18	21	23	16	18
	57.8	45.0	58.3	52.3	66.7	81.8
					b	BCD
Their grant payment process over all	95	16	23	21	17	18
	57.2	40.0	63.9	47.7	70.8	81.8
			B		Bd	BD
Their ability to liaise with the study sponsor	93	24	17	22	14	16
	56.0	60.0	47.2	50.0	58.3	72.7
						Cd
Providing fair grant payment amounts	91	17	22	16	17	19
	54.8	42.5	61.1	36.4	70.8	86.4
			bD		BD	BCD
Their ability to train site staff in study protocol	91	19	18	22	15	17
	54.8	47.5	50.0	50.0	62.5	77.3
						BCD
Providing reasonable grant payment schedules	83	16	18	17	15	17
	50.0	40.0	50.0	38.6	62.5	77.3
					bd	BCD

BCDComparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
CROPHARMA

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Providing prompt grant payments	82 49.4	16 40.0	21 58.3 D	15 34.1	14 58.3 D	16 72.7 BD
Being innovative in their support of patient recruitment	51 30.7	15 37.5 Cd	6 16.7	9 20.5	15 62.5 BCDF	6 27.3
CHI-SQUARE SIGNIFICANCE	<-----28.39-----> .3%					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Having low monitor turnover

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	96 57.8	18 45.0	21 58.3	23 52.3	16 66.7 b	18 81.8 BCD
Excellent (5)	50 30.1	10 25.0	8 22.2	7 15.9	13 54.2 BCD	12 54.5 BCD
Good (4)	46 27.7	8 20.0	13 36.1 E	16 36.4 bE	3 12.5	6 27.3
Three	39 23.5	10 25.0 f	8 22.2	16 36.4 EF	3 12.5	2 9.1
NOT GOOD/POOR (1 2)	21 12.7	8 20.0 F	6 16.7	4 9.1	2 8.3	1 4.5
Two	16 9.6	6 15.0	4 11.1	4 9.1	1 4.2	1 4.5
Poor (1)	5 3.0	2 5.0	2 5.6	-	1 4.2	-
Don't know	10 6.0	4 10.0	1 2.8	1 2.3	3 12.5	1 4.5
CHI-SQUARE SIGNIFICANCE	<-----30.289-----> 98.3%*					
MEAN	3.8	3.5 B	3.6 B	3.6 B	4.2 A	4.4 A
STANDARD DEVIATION	1.1	1.2	1.1	0.9	1.2	0.9
STANDARD ERROR	0.1	0.2	0.2	0.1	0.3	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Managing monitor turnover

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	96 57.8	17 42.5	18 50.0	23 52.3	17 70.8 Bc	21 95.5 BCDE
Excellent (5)	44 26.5	6 15.0	4 11.1	9 20.5	13 54.2 BCD	12 54.5 BCD
Good (4)	52 31.3	11 27.5	14 38.9 E	14 31.8	4 16.7	9 40.9 e
Three	39 23.5	15 37.5 cEF	7 19.4 EF	15 34.1 EF	1 4.2	1 4.5
NOT GOOD/POOR (1 2)	14 8.4	6 15.0	5 13.9	2 4.5	1 4.2	-
Two	9 5.4	4 10.0	3 8.3	1 2.3	1 4.2	-
Poor (1)	5 3.0	2 5.0	2 5.6	1 2.3	-	-
Don't know	17 10.2	2 5.0	6 16.7	4 9.1	5 20.8 b	-
CHI-SQUARE SIGNIFICANCE	<-----41.81-----> 100.0%*					
MEAN	3.8	3.4 B	3.5 B	3.7 B	4.5 A	4.5 A
STANDARD DEVIATION	1.0	1.1	1.1	0.9	0.8	0.6
STANDARD ERROR	0.1	0.2	0.2	0.1	0.2	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 Support for facilitating regulatory approvals

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	114 68.7	28 70.0	22 61.1	25 56.8	19 79.2 D	20 90.9 BCD
Excellent (5)	60 36.1	13 32.5	13 36.1	11 25.0	11 45.8 d	12 54.5 bD
Good (4)	54 32.5	15 37.5	9 25.0	14 31.8	8 33.3	8 36.4
Three	24 14.5	5 12.5	6 16.7 e	10 22.7 E	1 4.2	2 9.1
NOT GOOD/POOR (1 2)	9 5.4	4 10.0	1 2.8	4 9.1	-	-
Two	9 5.4	4 10.0	1 2.8	4 9.1	-	-
Poor (1)	-	-	-	-	-	-
Don't know	19 11.4	3 7.5	7 19.4	5 11.4	4 16.7	-
CHI-SQUARE SIGNIFICANCE	<-----14.591-----> 73.5%*					
MEAN	4.1	4.0 CB	4.2 CBA	3.8 C	4.5 A	4.5 BA
STANDARD DEVIATION	0.9	1.0	0.9	1.0	0.6	0.7
STANDARD ERROR	0.1	0.2	0.2	0.2	0.1	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 Maintaining the availability of clinical trial supplies

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	117 70.5	28 70.0 C	16 44.4	33 75.0 C	19 79.2 C	21 95.5 BCDe
Excellent (5)	53 31.9	6 15.0	5 13.9	8 18.2	17 70.8 BCD	17 77.3 BCD
Good (4)	64 38.6	22 55.0 CEF	11 30.6 E	25 56.8 CEF	2 8.3	4 18.2
Three	27 16.3	10 25.0 EF	7 19.4 EF	8 18.2 Ef	1 4.2	1 4.5
NOT GOOD/POOR (1 2)	10 6.0	2 5.0	4 11.1	3 6.8	1 4.2	-
Two	9 5.4	1 2.5	4 11.1	3 6.8	1 4.2	-
Poor (1)	1 0.6	1 2.5	-	-	-	-
Don't know	12 7.2	-	9 25.0	-	3 12.5	-
CHI-SQUARE SIGNIFICANCE	<-----62.146-----> 100.0%*					
MEAN	4.0	3.8 B	3.6 B	3.9 B	4.7 A	4.7 A
STANDARD DEVIATION	0.9	0.8	1.0	0.8	0.8	0.6
STANDARD ERROR	0.1	0.1	0.2	0.1	0.2	0.1

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Being innovative in their support of patient recruitment

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	51 30.7	15 37.5 Cd	6 16.7	9 20.5	15 62.5 BCDF	6 27.3
Excellent (5)	20 12.0	4 10.0	1 2.8	-	12 50.0 BCF	3 13.6
Good (4)	31 18.7	11 27.5	5 13.9	9 20.5	3 12.5	3 13.6
Three	38 22.9	8 20.0	11 30.6 E	14 31.8 Ef	2 8.3	3 13.6
NOT GOOD/POOR (1 2)	43 25.9	15 37.5 EF	10 27.8	12 27.3	3 12.5	3 13.6
Two	28 16.9	9 22.5	7 19.4	8 18.2	2 8.3	2 9.1
Poor (1)	15 9.0	6 15.0	3 8.3	4 9.1	1 4.2	1 4.5
Don't know	34 20.5	2 5.0	9 25.0 B	9 20.5 B	4 16.7	10 45.5 BDE
CHI-SQUARE SIGNIFICANCE	<-----46.334-----> 100.0%*					
MEAN	3.1	2.9 B	2.8 B	2.8 B	4.2 A	3.4 BA
STANDARD DEVIATION	1.2	1.3	1.0	1.0	1.3	1.3
STANDARD ERROR	0.1	0.2	0.2	0.2	0.3	0.4

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 Their ability to train site staff in study protocol

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	91 54.8	19 47.5	18 50.0	22 50.0	15 62.5	17 77.3 BCD
Excellent (5)	42 25.3	8 20.0	5 13.9	5 11.4	14 58.3 BCD	10 45.5 BCD
Good (4)	49 29.5	11 27.5 E	13 36.1 E	17 38.6 E	1 4.2	7 31.8 E
Three	40 24.1	12 30.0	9 25.0	10 22.7	5 20.8	4 18.2
NOT GOOD/POOR (1 2)	18 10.8	4 10.0	4 11.1	8 18.2	2 8.3	-
Two	14 8.4	3 7.5	3 8.3	7 15.9 e	1 4.2	-
Poor (1)	4 2.4	1 2.5	1 2.8	1 2.3	1 4.2	-
Don't know	17 10.2	5 12.5	5 13.9	4 9.1	2 8.3	1 4.5
CHI-SQUARE SIGNIFICANCE	<-----33.039-----> 99.3%*					
MEAN	3.7	3.6 B	3.6 B	3.5 B	4.2 A	4.3 A
STANDARD DEVIATION	1.1	1.0	1.0	1.0	1.2	0.8
STANDARD ERROR	0.1	0.2	0.2	0.2	0.3	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Their ability to liaise with the study sponsor

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	93 56.0	24 60.0	17 47.2	22 50.0	14 58.3	16 72.7 cd
Excellent (5)	36 21.7	7 17.5 c	2 5.6	4 9.1	12 50.0 BCD	11 50.0 BCD
Good (4)	57 34.3	17 42.5 Ef	15 41.7 E	18 40.9 E	2 8.3	5 22.7
Three	32 19.3	8 20.0 EF	7 19.4 EF	15 34.1 EF	1 4.2	1 4.5
NOT GOOD/POOR (1 2)	11 6.6	4 10.0	2 5.6	3 6.8	2 8.3	-
Two	10 6.0	4 10.0	2 5.6	2 4.5	2 8.3	-
Poor (1)	1 0.6	-	-	1 2.3	-	-
Don't know	30 18.1	4 10.0	10 27.8 BD	4 9.1	7 29.2 bD	5 22.7
CHI-SQUARE SIGNIFICANCE	<-----49.39-----> 100.0%*					
MEAN	3.9	3.8 B	3.7 B	3.6 B	4.4 A	4.6 A
STANDARD DEVIATION	0.9	0.9	0.7	0.8	1.1	0.6
STANDARD ERROR	0.1	0.2	0.1	0.1	0.3	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 The quality of their CRAs over all

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	124 74.7	24 60.0	27 75.0	31 70.5	20 83.3 B	22 100.0 BCDE
Excellent (5)	44 26.5	10 25.0	4 11.1	7 15.9	12 50.0 BCD	11 50.0 BCD
Good (4)	80 48.2	14 35.0	23 63.9 BE	24 54.5 be	8 33.3	11 50.0
Three	33 19.9	10 25.0	7 19.4	13 29.5 e	3 12.5	-
NOT GOOD/POOR (1 2)	7 4.2	5 12.5 c	1 2.8	-	1 4.2	-
Two	6 3.6	5 12.5	-	-	1 4.2	-
Poor (1)	1 0.6	-	1 2.8	-	-	-
Don't know	2 1.2	1 2.5	1 2.8	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----43.138-----> 100.0%*					
MEAN	4.0	3.7 B	3.8 B	3.9 B	4.3 A	4.5 A
STANDARD DEVIATION	0.8	1.0	0.7	0.7	0.9	0.5
STANDARD ERROR	0.1	0.2	0.1	0.1	0.2	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 Providing well designed case report forms

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	115 69.3	22 55.0	28 77.8 BD	23 52.3	21 87.5 BD	21 95.5 BCD
Excellent (5)	52 31.3	7 17.5	6 16.7	4 9.1	15 62.5 BCD	20 90.9 BCDE
Good (4)	63 38.0	15 37.5 F	22 61.1 BEF	19 43.2 F	6 25.0 F	1 4.5
Three	29 17.5	8 20.0	6 16.7	12 27.3	3 12.5	-
NOT GOOD/POOR (1 2)	17 10.2	8 20.0 cF	2 5.6	6 13.6	-	1 4.5
Two	14 8.4	7 17.5 cF	1 2.8	5 11.4	-	1 4.5
Poor (1)	3 1.8	1 2.5	1 2.8	1 2.3	-	-
Don't know	5 3.0	2 5.0	-	3 6.8	-	-
CHI-SQUARE SIGNIFICANCE	<-----71.935-----> 100.0%*					
MEAN	3.9	3.5 B	3.9 B	3.5 B	4.5 A	4.8 A
STANDARD DEVIATION	1.0	1.1	0.8	0.9	0.7	0.7
STANDARD ERROR	0.1	0.2	0.1	0.1	0.1	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Having an efficient data query handling process

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	111 66.9	22 55.0	22 61.1	30 68.2	18 75.0	19 86.4 BCd
Excellent (5)	40 24.1	2 5.0	7 19.4 b	9 20.5 B	9 37.5 B	13 59.1 BCD
Good (4)	71 42.8	20 50.0 f	15 41.7	21 47.7 f	9 37.5	6 27.3
Three	30 18.1	10 25.0 ef	7 19.4	9 20.5	2 8.3	2 9.1
NOT GOOD/POOR (1 2)	13 7.8	5 12.5	3 8.3	3 6.8	2 8.3	-
Two	11 6.6	3 7.5	3 8.3	3 6.8	2 8.3	-
Poor (1)	2 1.2	2 5.0	-	-	-	-
Don't know	12 7.2	3 7.5	4 11.1	2 4.5	2 8.3	1 4.5
CHI-SQUARE SIGNIFICANCE	<-----32.832-----> 99.2%*					
MEAN	3.9	3.5 C	3.8 CB	3.9 B	4.1 BA	4.5 A
STANDARD DEVIATION	0.9	0.9	0.9	0.8	0.9	0.7
STANDARD ERROR	0.1	0.2	0.2	0.1	0.2	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 CROPHARMA RATING
 Providing fair grant payment amounts

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	91 54.8	17 42.5	22 61.1 bD	16 36.4	17 70.8 BD	19 86.4 BCD
Excellent (5)	36 21.7	3 7.5	8 22.2 b	5 11.4	9 37.5 BD	11 50.0 BCD
Good (4)	55 33.1	14 35.0	14 38.9	11 25.0	8 33.3	8 36.4
Three	43 25.9	12 30.0 E	11 30.6 E	15 34.1 EF	2 8.3	3 13.6
NOT GOOD/POOR (1 2)	12 7.2	5 12.5 c	1 2.8	4 9.1	2 8.3	-
Two	9 5.4	4 10.0	1 2.8	3 6.8	1 4.2	-
Poor (1)	3 1.8	1 2.5	-	1 2.3	1 4.2	-
Don't know	20 12.0	6 15.0	2 5.6	9 20.5 C	3 12.5	-
CHI-SQUARE SIGNIFICANCE	<-----27.669-----> 96.5%*					
MEAN	3.8	3.4 D	3.9 CB	3.5	4.1 BA	4.4 A
STANDARD DEVIATION	1.0	0.9	0.8	1.0	1.1	0.7
STANDARD ERROR	0.1	0.2	0.1	0.2	0.2	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Providing reasonable grant payment schedules

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	83 50.0	16 40.0	18 50.0	17 38.6	15 62.5 bd	17 77.3 BCD
Excellent (5)	34 20.5	2 5.0	4 11.1	3 6.8	9 37.5 BCD	16 72.7 BCDE
Good (4)	49 29.5	14 35.0 F	14 38.9 F	14 31.8 F	6 25.0 F	1 4.5
Three	45 27.1	12 30.0 F	11 30.6 F	15 34.1 F	5 20.8	2 9.1
NOT GOOD/POOR (1 2)	12 7.2	6 15.0 c	1 2.8	2 4.5	1 4.2	2 9.1
Two	5 3.0	2 5.0	1 2.8	1 2.3	-	1 4.5
Poor (1)	7 4.2	4 10.0	-	1 2.3	1 4.2	1 4.5
Don't know	26 15.7	6 15.0	6 16.7	10 22.7 F	3 12.5	1 4.5
CHI-SQUARE SIGNIFICANCE	<-----55.389-----> 100.0%*					
MEAN	3.7	3.2 C	3.7 CB	3.5 C	4.0 BA	4.4 A
STANDARD DEVIATION	1.0	1.1	0.7	0.8	1.1	1.2
STANDARD ERROR	0.1	0.2	0.1	0.1	0.2	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Providing prompt grant payments

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	82 49.4	16 40.0	21 58.3 D	15 34.1	14 58.3 D	16 72.7 BD
Excellent (5)	38 22.9	6 15.0	6 16.7	4 9.1	9 37.5 BcD	13 59.1 BCD
Good (4)	44 26.5	10 25.0	15 41.7 eF	11 25.0	5 20.8	3 13.6
Three	38 22.9	8 20.0	7 19.4	18 40.9 BCEF	2 8.3	3 13.6
NOT GOOD/POOR (1 2)	21 12.7	9 22.5 cd	3 8.3	4 9.1	3 12.5	2 9.1
Two	13 7.8	6 15.0	3 8.3	2 4.5	1 4.2	1 4.5
Poor (1)	8 4.8	3 7.5	-	2 4.5	2 8.3	1 4.5
Don't know	25 15.1	7 17.5 f	5 13.9	7 15.9	5 20.8 f	1 4.5
CHI-SQUARE SIGNIFICANCE	<-----40.108-----> 99.9%*					
MEAN	3.6	3.3 C	3.8 CBA	3.4 CB	3.9 BA	4.2 A
STANDARD DEVIATION	1.1	1.2	0.9	0.9	1.4	1.2
STANDARD ERROR	0.1	0.2	0.2	0.2	0.3	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
CROPHARMA RATING
Their grant payment process over all

FILTER: RATED CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	166 100.0	40 100.0	36 100.0	44 100.0	24 100.0	22 100.0
EXCELLENT/GOOD (4 5)	95 57.2	16 40.0	23 63.9 B	21 47.7	17 70.8 Bd	18 81.8 BD
Excellent (5)	35 21.1	2 5.0	8 22.2 B	6 13.6	9 37.5 BD	10 45.5 BcD
Good (4)	60 36.1	14 35.0	15 41.7	15 34.1	8 33.3	8 36.4
Three	32 19.3	10 25.0 e	7 19.4	10 22.7 e	2 8.3	3 13.6
NOT GOOD/POOR (1 2)	12 7.2	7 17.5	-	5 11.4	-	-
Two	6 3.6	3 7.5	-	3 6.8	-	-
Poor (1)	6 3.6	4 10.0	-	2 4.5	-	-
Don't know	27 16.3	7 17.5 f	6 16.7	8 18.2 f	5 20.8 f	1 4.5
CHI-SQUARE SIGNIFICANCE			<-----31.261-----> 98.8%*			
MEAN	3.8	3.2 B	4.0 A	3.6 B	4.4 A	4.3 A
STANDARD DEVIATION	1.0	1.1	0.7	1.1	0.7	0.7
STANDARD ERROR	0.1	0.2	0.1	0.2	0.2	0.2

Comparison Groups: BCDEF
Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MEAN SUMMARY CRA RATINGS
 BETA THERAPEUTIC

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
The quality of their CRAs over all	4.0	3.7 C	4.0 CBA	3.9 CB	4.8 A	4.6 BA
Maintaining the availability of clinical trial supplies	4.0	3.9 BA	3.4 B	3.9 B	5.0 A	4.4 BA
Managing monitor turnover	3.8	3.3 CB	3.3 C	4.1 BA	3.7 CBA	5.0 A
Having an efficient data query handling process	3.8	3.5 B	3.5 B	3.7 B	4.3 BA	5.0 A
Support for facilitating regulatory approvals	3.8	3.4 B	4.3 A	3.4 B	4.8 A	4.5 A
Providing well designed case report forms	3.8	3.6 B	3.9 B	3.6 B	4.0 B	5.0 A
Their grant payment process over all	3.8	3.1 C	4.2 BA	3.6 CB	4.5 BA	4.6 A
Their ability to train site staff in study protocol	3.7	3.4 C	3.0 C	3.7 CB	4.7 BA	4.8 A
Having low monitor turnover	3.7	3.5 A	3.8 A	3.5 A	4.7 A	4.5 A
Providing prompt grant payments	3.7	3.3 C	3.5 CBA	3.5 CB	4.5 BA	4.8 A
Providing fair grant payment amounts	3.6	3.3 B	3.6 BA	3.4 B	4.5 A	4.6 A
Providing reasonable grant payment schedules	3.6	3.0 C	3.8 CBA	3.3 CB	4.3 BA	4.8 A
Their ability to liaise with the study sponsor	3.6	3.6 CB	2.6 C	3.6 B	4.0 BA	4.8 A
Being innovative in their support of patient recruitment	2.7	2.5 B	2.5 B	2.6 B	4.3 A	2.0 B
CHI-SQUARE SIGNIFICANCE	<-----6.259-----> .0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP BOX (5) CRA RATINGS
BETA THERAPEUTIC

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
Maintaining the availability of clinical trial supplies	13 26.5	2 20.0	-	5 22.7	3 75.0 BD	3 60.0
Having low monitor turnover	12 24.5	2 20.0	1 12.5	4 18.2	2 50.0	3 60.0 cd
Having an efficient data query handling process	12 24.5	1 10.0	1 12.5	3 13.6	3 75.0 BCD	4 80.0 BCD
Their grant payment process over all	12 24.5	1 10.0	2 25.0	3 13.6	3 75.0 BcD	3 60.0 BD
The quality of their CRAs over all	11 22.4	2 20.0	1 12.5	2 9.1	3 75.0 BCD	3 60.0 cD
Providing prompt grant payments	10 20.4	2 20.0	-	2 9.1	3 75.0 BD	3 60.0 D
Managing monitor turnover	10 20.4	1 10.0	-	4 18.2	1 25.0	4 80.0 BDe
Support for facilitating regulatory approvals	9 18.4	-	2 25.0	2 9.1	3 75.0 cD	2 40.0
Providing reasonable grant payment schedules	9 18.4	1 10.0	-	2 9.1	2 50.0	4 80.0 BD
Providing fair grant payment amounts	8 16.3	-	-	3 13.6	2 50.0	3 60.0 D
Their ability to liaise with the study sponsor	8 16.3	1 10.0	-	2 9.1	2 50.0	3 60.0 BD
Providing well designed case report forms	7 14.3	1 10.0	-	1 4.5	1 25.0	4 80.0

BDeComparison Groups: BCDEF

Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are
significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP BOX (5) CRA RATINGS
BETA THERAPEUTIC

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Their ability to train site staff in study protocol	7 14.3	1 10.0	-	1 4.5	2 50.0 d	3 60.0 BD
Being innovative in their support of patient recruitment	3 6.1	1 10.0	-	-	2 50.0	-
CHI-SQUARE SIGNIFICANCE	<-----29.888-----> .6%*					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.
*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP 2 BOX (4 5) CRA RATINGS
 BETA THERAPEUTIC

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
The quality of their CRAs over all	36 73.5	7 70.0	5 62.5	15 68.2	4 100.0 BCD	5 100.0 BCD
Maintaining the availability of clinical trial supplies	33 67.3	7 70.0 C	2 25.0	17 77.3 C	3 75.0 c	4 80.0 C
Providing well designed case report forms	30 61.2	6 60.0	6 75.0	11 50.0	3 75.0	4 80.0
Having an efficient data query handling process	29 59.2	7 70.0	3 37.5	12 54.5	3 75.0	4 80.0 c
Managing monitor turnover	27 55.1	4 40.0	4 50.0	13 59.1	2 50.0	4 80.0 b
Their ability to train site staff in study protocol	26 53.1	5 50.0	3 37.5	11 50.0	3 75.0	4 80.0 c
Their grant payment process over all	26 53.1	4 40.0	5 62.5	9 40.9	3 75.0	5 100.0 BCD
Providing fair grant payment amounts	25 51.0	5 50.0	4 50.0	7 31.8	4 100.0 BCD	5 100.0 BCD
Support for facilitating regulatory approvals	25 51.0	4 40.0	6 75.0 D	7 31.8	4 100.0 BD	4 80.0 bD
Providing prompt grant payments	24 49.0	4 40.0	4 50.0	9 40.9	3 75.0	4 80.0 bd
Having low monitor turnover	24 49.0	5 50.0	5 62.5	8 36.4	3 75.0	3 60.0
Their ability to liaise with the study sponsor	22 44.9	6 60.0 C	1 12.5	9 40.9 c	2 50.0	4 80.0 Cd

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
BETA THERAPEUTIC

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Providing reasonable grant payment schedules	22 44.9	3 30.0	5 62.5 d	6 27.3	3 75.0 bD	5 100.0 BCD
Being innovative in their support of patient recruitment	9 18.4	1 10.0	2 25.0	3 13.6	3 75.0 BcD	-
CHI-SQUARE SIGNIFICANCE	<-----23.927-----> .0%*					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are
significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Having low monitor turnover

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	24 49.0	5 50.0	5 62.5	8 36.4	3 75.0	3 60.0
Excellent (5)	12 24.5	2 20.0	1 12.5	4 18.2	2 50.0	3 60.0 cd
Good (4)	12 24.5	3 30.0	4 50.0	4 18.2	1 25.0	-
Three	16 32.7	3 30.0	3 37.5	9 40.9	-	1 20.0
NOT GOOD/POOR (1 2)	4 8.2	2 20.0	-	2 9.1	-	-
Two	4 8.2	2 20.0	-	2 9.1	-	-
Poor (1)	-	-	-	-	-	-
Don't know	5 10.2	-	-	3 13.6	1 25.0	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----13.791-----> 68.6%*					
MEAN	3.7	3.5	3.8	3.5	4.7	4.5
STANDARD DEVIATION	1.0	A	A	A	A	A
STANDARD ERROR	0.1	0.3	0.3	0.2	0.3	0.5

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Managing monitor turnover

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	27 55.1	4 40.0	4 50.0	13 59.1	2 50.0	4 80.0 b
Excellent (5)	10 20.4	1 10.0	-	4 18.2	1 25.0	4 80.0 BDe
Good (4)	17 34.7	3 30.0	4 50.0	9 40.9	1 25.0	-
Three	9 18.4	3 30.0	3 37.5	3 13.6	-	-
NOT GOOD/POOR (1 2)	4 8.2	2 20.0	1 12.5	-	1 25.0	-
Two	3 6.1	2 20.0	-	-	1 25.0	-
Poor (1)	1 2.0	-	1 12.5	-	-	-
Don't know	9 18.4	1 10.0	-	6 27.3	1 25.0	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----28.847-----> 97.5%*					
MEAN	3.8	3.3	3.3	4.1	3.7	5.0
STANDARD DEVIATION	1.0	1.0	1.0	0.7	1.5	0.0
STANDARD ERROR	0.2	0.3	0.4	0.2	0.9	0.0

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
BETA THERAPEUTIC RATING
Support for facilitating regulatory approvals

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	25 51.0	4 40.0	6 75.0 D	7 31.8	4 100.0 BD	4 80.0 bD
Excellent (5)	9 18.4	-	2 25.0	2 9.1	3 75.0 cD	2 40.0
Good (4)	16 32.7	4 40.0	4 50.0	5 22.7	1 25.0	2 40.0
Three	10 20.4	3 30.0	-	7 31.8	-	-
NOT GOOD/POOR (1 2)	3 6.1	1 10.0	-	2 9.1	-	-
Two	2 4.1	1 10.0	-	1 4.5	-	-
Poor (1)	1 2.0	-	-	1 4.5	-	-
Don't know	11 22.4	2 20.0	2 25.0	6 27.3	-	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----19.206-----> 74.2%*					
MEAN	3.8	3.4	4.3	3.4	4.8	4.5
STANDARD DEVIATION	1.0	B 0.7	A 0.5	B 1.0	A 0.5	A 0.6
STANDARD ERROR	0.2	0.3	0.2	0.3	0.3	0.3

Comparison Groups: BCDEF
Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Maintaining the availability of clinical trial supplies

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	33 67.3	7 70.0 C	2 25.0	17 77.3 C	3 75.0 c	4 80.0 C
Excellent (5)	13 26.5	2 20.0	-	5 22.7	3 75.0 BD	3 60.0
Good (4)	20 40.8	5 50.0	2 25.0	12 54.5 f	-	1 20.0
Three	10 20.4	3 30.0	3 37.5	3 13.6	-	1 20.0
NOT GOOD/POOR (1 2)	2 4.1	-	-	2 9.1	-	-
Two	1 2.0	-	-	1 4.5	-	-
Poor (1)	1 2.0	-	-	1 4.5	-	-
Don't know	4 8.2	-	3 37.5	-	1 25.0	-
CHI-SQUARE SIGNIFICANCE	<-----18.518-----> 70.6%*					
MEAN	4.0	3.9 BA	3.4 B	3.9 B	5.0 A	4.4 BA
STANDARD DEVIATION	0.9	0.7	0.5	1.0	0.0	0.9
STANDARD ERROR	0.1	0.2	0.2	0.2	0.0	0.4

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Being innovative in their support of patient recruitment

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	9 18.4	1 10.0	2 25.0	3 13.6	3 75.0 BCD	-
Excellent (5)	3 6.1	1 10.0	-	-	2 50.0	-
Good (4)	6 12.2	-	2 25.0	3 13.6	1 25.0	-
Three	16 32.7	5 50.0 c	1 12.5	8 36.4	1 25.0	1 20.0
NOT GOOD/POOR (1 2)	18 36.7	4 40.0	3 37.5	9 40.9	-	2 40.0
Two	10 20.4	1 10.0	1 12.5	7 31.8	-	1 20.0
Poor (1)	8 16.3	3 30.0	2 25.0	2 9.1	-	1 20.0
Don't know	6 12.2	-	2 25.0	2 9.1	-	2 40.0
CHI-SQUARE SIGNIFICANCE	<-----24.298-----> 91.7%*					
MEAN	2.7	2.5 B	2.5 B	2.6 B	4.3 A	2.0 B
STANDARD DEVIATION	1.1	1.3	1.4	0.9	1.0	1.0
STANDARD ERROR	0.2	0.4	0.6	0.2	0.5	0.6

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Their ability to train site staff in study protocol

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49	10	8	22	4	5
	100.0	100.0	100.0	100.0	100.0	100.0
EXCELLENT/GOOD (4 5)	26	5	3	11	3	4
	53.1	50.0	37.5	50.0	75.0	80.0
						c
Excellent (5)	7	1	-	1	2	3
	14.3	10.0		4.5	50.0	60.0
					d	BD
Good (4)	19	4	3	10	1	1
	38.8	40.0	37.5	45.5	25.0	20.0
Three	8	2	-	6	-	-
	16.3	20.0		27.3		
NOT GOOD/POOR (1 2)	4	2	2	-	-	-
	8.2	20.0	25.0			
Two	3	2	1	-	-	-
	6.1	20.0	12.5			
Poor (1)	1	-	1	-	-	-
	2.0		12.5			
Don't know	11	1	3	5	1	1
	22.4	10.0	37.5	22.7	25.0	20.0
CHI-SQUARE	<-----30.395----->					
SIGNIFICANCE	98.4%*					
MEAN	3.7	3.4	3.0	3.7	4.7	4.8
		C	C	CB	BA	A
STANDARD DEVIATION	0.9	1.0	1.4	0.6	0.6	0.5
STANDARD ERROR	0.2	0.3	0.6	0.1	0.3	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
BETA THERAPEUTIC RATING
Their ability to liaise with the study sponsor

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	22 44.9	6 60.0	1 12.5	9 40.9	2 50.0	4 80.0
		C		c		Cd
Excellent (5)	8 16.3	1 10.0	-	2 9.1	2 50.0	3 60.0
						BD
Good (4)	14 28.6	5 50.0	1 12.5	7 31.8	-	1 20.0
		c				
Three	13 26.5	1 10.0	2 25.0	10 45.5	-	-
				B		
NOT GOOD/POOR (1 2)	5 10.2	2 20.0	2 25.0	-	1 25.0	-
Two	4 8.2	2 20.0	1 12.5	-	1 25.0	-
Poor (1)	1 2.0	-	1 12.5	-	-	-
Don't know	9 18.4	1 10.0	3 37.5	3 13.6	1 25.0	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----32.891-----> 99.2%*					
MEAN	3.6	3.6	2.6	3.6	4.0	4.8
		CB	C	B	BA	A
STANDARD DEVIATION	1.0	1.0	1.1	0.7	1.7	0.5
STANDARD ERROR	0.2	0.3	0.5	0.2	1.0	0.3

Comparison Groups: BCDEF
Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 The quality of their CRAs over all

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	36 73.5	7 70.0	5 62.5	15 68.2	4 100.0 BCD	5 100.0 BCD
Excellent (5)	11 22.4	2 20.0	1 12.5	2 9.1	3 75.0 BCD	3 60.0 cD
Good (4)	25 51.0	5 50.0	4 50.0	13 59.1	1 25.0	2 40.0
Three	6 12.2	1 10.0	1 12.5	4 18.2	-	-
NOT GOOD/POOR (1 2)	2 4.1	2 20.0	-	-	-	-
Two	2 4.1	2 20.0	-	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	5 10.2	-	2 25.0	3 13.6	-	-
CHI-SQUARE SIGNIFICANCE	<-----18.836-----> 90.7%*					
MEAN	4.0	3.7	4.0	3.9	4.8	4.6
STANDARD DEVIATION	0.8	1.1	0.6	0.6	0.5	0.5
STANDARD ERROR	0.1	0.3	0.3	0.1	0.3	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Providing well designed case report forms

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	30 61.2	6 60.0	6 75.0	11 50.0	3 75.0	4 80.0
Excellent (5)	7 14.3	1 10.0	-	1 4.5	1 25.0	4 80.0 BDe
Good (4)	23 46.9	5 50.0	6 75.0	10 45.5	2 50.0	-
Three	13 26.5	3 30.0	1 12.5	8 36.4	1 25.0	-
NOT GOOD/POOR (1 2)	2 4.1	1 10.0	-	1 4.5	-	-
Two	2 4.1	1 10.0	-	1 4.5	-	-
Poor (1)	-	-	-	-	-	-
Don't know	4 8.2	-	1 12.5	2 9.1	-	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----28.905-----> 99.6%*					
MEAN	3.8	3.6	3.9	3.6	4.0	5.0
STANDARD DEVIATION	0.8	B	B	B	B	A
STANDARD ERROR	0.1	0.3	0.1	0.2	0.4	0.0

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Having an efficient data query handling process

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	29 59.2	7 70.0	3 37.5	12 54.5	3 75.0	4 80.0 c
Excellent (5)	12 24.5	1 10.0	1 12.5	3 13.6	3 75.0 BCD	4 80.0 BCD
Good (4)	17 34.7	6 60.0	2 25.0	9 40.9	-	-
Three	10 20.4	1 10.0	2 25.0	7 31.8	-	-
NOT GOOD/POOR (1 2)	5 10.2	2 20.0	1 12.5	1 4.5	1 25.0	-
Two	4 8.2	1 10.0	1 12.5	1 4.5	1 25.0	-
Poor (1)	1 2.0	1 10.0	-	-	-	-
Don't know	5 10.2	-	2 25.0	2 9.1	-	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----27.857-----> 96.7%*					
MEAN	3.8	3.5	3.5	3.7	4.3	5.0
STANDARD DEVIATION	1.0	B	B	B	BA	A
STANDARD ERROR	0.2	1.2	1.0	0.8	1.5	0.0
	0.2	0.4	0.4	0.2	0.8	0.0

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Providing fair grant payment amounts

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	25 51.0	5 50.0	4 50.0	7 31.8	4 100.0 BCD	5 100.0 BCD
Excellent (5)	8 16.3	-	-	3 13.6	2 50.0	3 60.0 D
Good (4)	17 34.7	5 50.0 d	4 50.0	4 18.2	2 50.0	2 40.0
Three	13 26.5	3 30.0	3 37.5	7 31.8	-	-
NOT GOOD/POOR (1 2)	5 10.2	2 20.0	-	3 13.6	-	-
Two	4 8.2	2 20.0	-	2 9.1	-	-
Poor (1)	1 2.0	-	-	1 4.5	-	-
Don't know	6 12.2	-	1 12.5	5 22.7	-	-
CHI-SQUARE SIGNIFICANCE	<-----20.057-----> 78.2%*					
MEAN	3.6	3.3 B	3.6 BA	3.4 B	4.5 A	4.6 A
STANDARD DEVIATION	1.0	0.8	0.5	1.1	0.6	0.5
STANDARD ERROR	0.1	0.3	0.2	0.3	0.3	0.2

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Providing reasonable grant payment schedules

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	22 44.9	3 30.0	5 62.5 d	6 27.3	3 75.0 bD	5 100.0 BCD
Excellent (5)	9 18.4	1 10.0	-	2 9.1	2 50.0	4 80.0 BD
Good (4)	13 26.5	2 20.0	5 62.5 BDF	4 18.2	1 25.0	1 20.0
Three	9 18.4	4 40.0	1 12.5	3 13.6	1 25.0	-
NOT GOOD/POOR (1 2)	7 14.3	3 30.0	-	4 18.2	-	-
Two	6 12.2	2 20.0	-	4 18.2	-	-
Poor (1)	1 2.0	1 10.0	-	-	-	-
Don't know	11 22.4	-	2 25.0	9 40.9	-	-
CHI-SQUARE SIGNIFICANCE	<-----25.283-----> 93.5%*					
MEAN	3.6	3.0 C	3.8 CBA	3.3 CB	4.3 BA	4.8 A
STANDARD DEVIATION	1.1	1.2	0.4	1.1	1.0	0.4
STANDARD ERROR	0.2	0.4	0.2	0.3	0.5	0.2

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Providing prompt grant payments

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	49 100.0	10 100.0	8 100.0	22 100.0	4 100.0	5 100.0
EXCELLENT/GOOD (4 5)	24 49.0	4 40.0	4 50.0	9 40.9	3 75.0	4 80.0 bd
Excellent (5)	10 20.4	2 20.0	-	2 9.1	3 75.0 BD	3 60.0 D
Good (4)	14 28.6	2 20.0	4 50.0	7 31.8	-	1 20.0
Three	11 22.4	4 40.0	1 12.5	5 22.7	1 25.0	-
NOT GOOD/POOR (1 2)	6 12.2	2 20.0	1 12.5	3 13.6	-	-
Two	5 10.2	1 10.0	1 12.5	3 13.6	-	-
Poor (1)	1 2.0	1 10.0	-	-	-	-
Don't know	8 16.3	-	2 25.0	5 22.7	-	1 20.0
CHI-SQUARE SIGNIFICANCE	<-----21.835-----> 85.1%*					
MEAN	3.7	3.3	3.5	3.5	4.5	4.8
STANDARD DEVIATION	1.1	C	CBA	CB	BA	A
STANDARD ERROR	0.2	1.3	0.8	0.9	1.0	0.5
	0.2	0.4	0.3	0.2	0.5	0.3

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 BETA THERAPEUTIC RATING
 Their grant payment process over all

FILTER: RATED BETA THERAPEUTIC

	<----- COUNTRY ----->						
	TOTAL	UK	Germany	France	Ireland	Spain	
	(A)	(B)	(C)	(D)	(E)	(F)	
TOTAL	49	10	8	22	4	5	
	100.0	100.0	100.0	100.0	100.0	100.0	
EXCELLENT/GOOD (4 5)	26	4	5	9	3	5	
	53.1	40.0	62.5	40.9	75.0	100.0	
						BCD	
Excellent (5)	12	1	2	3	3	3	
	24.5	10.0	25.0	13.6	75.0	60.0	
					BcD	BD	
Good (4)	14	3	3	6	-	2	
	28.6	30.0	37.5	27.3		40.0	
Three	11	3	1	6	1	-	
	22.4	30.0	12.5	27.3	25.0		
NOT GOOD/POOR (1 2)	5	3	-	2	-	-	
	10.2	30.0		9.1			
Two	4	2	-	2	-	-	
	8.2	20.0		9.1			
Poor (1)	1	1	-	-	-	-	
	2.0	10.0					
Don't know	7	-	2	5	-	-	
	14.3		25.0	22.7			
CHI-SQUARE			<-----16.648----->				
SIGNIFICANCE			59.1%*				
MEAN	3.8	3.1	4.2	3.6	4.5	4.6	
		C	BA	CB	BA	A	
STANDARD DEVIATION	1.1	1.2	0.8	0.9	1.0	0.5	
STANDARD ERROR	0.2	0.4	0.3	0.2	0.5	0.2	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MEAN SUMMARY CRA RATINGS
 MATRIX, INC.

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
Support for facilitating regulatory approvals	4.1	4.0	4.3	3.7	4.5	3.3
Maintaining the availability of clinical trial supplies	4.0	4.0	3.7	3.6	4.4	4.7
The quality of their CRAs over all	3.9	3.8 BA	3.7 B	3.6 B	4.6 A	4.3 BA
Having an efficient data query handling process	3.9	4.0 BA	3.8 B	3.6 B	4.1 BA	5.0 A
Their grant payment process over all	3.9	2.6	4.1	3.9	4.3	4.3
Providing fair grant payment amounts	3.8	3.6	3.7	3.6	4.3	4.0
Providing well designed case report forms	3.8	3.7 CB	3.9 CB	3.2 C	4.0 BA	5.0 A
Managing monitor turnover	3.7	2.8	3.6	3.8	4.3	4.7
Providing reasonable grant payment schedules	3.7	2.8	3.9	3.8	3.8	4.3
Providing prompt grant payments	3.7	3.0	3.7	3.2	4.1	5.0
Having low monitor turnover	3.6	3.7	3.5	3.4	3.7	4.3
Their ability to train site staff in study protocol	3.6	3.5	3.4	3.0	4.3	4.0
Their ability to liaise with the study sponsor	3.5	3.4	2.8	3.1	4.4	5.0
Being innovative in their support of patient recruitment	2.8	2.5	2.6	2.5	3.7	1.0
CHI-SQUARE SIGNIFICANCE	<-----4.31-----> .0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP BOX (5) CRA RATINGS
 MATRIX, INC.

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
Support for facilitating regulatory approvals	12 31.6	1 16.7	5 50.0 D	1 10.0	4 44.4 d	1 33.3
Maintaining the availability of clinical trial supplies	10 26.3	1 16.7	1 10.0	1 10.0	5 55.6 bcd	2 66.7 CD
The quality of their CRAs over all	10 26.3	1 16.7	2 20.0	-	6 66.7 BC	1 33.3
Having an efficient data query handling process	10 26.3	1 16.7	2 20.0	-	4 44.4	3 100.0 BCE
Their grant payment process over all	9 23.7	-	3 30.0	1 10.0	4 44.4 d	1 33.3
Providing prompt grant payments	8 21.1	-	1 10.0	-	4 44.4 c	3 100.0 CE
Providing reasonable grant payment schedules	8 21.1	-	2 20.0	1 10.0	3 33.3	2 66.7 D
Providing well designed case report forms	7 18.4	2 33.3	-	-	2 22.2	3 100.0 BE
Managing monitor turnover	7 18.4	-	1 10.0	-	4 44.4 c	2 66.7 C
Providing fair grant payment amounts	7 18.4	-	1 10.0	1 10.0	4 44.4 cd	1 33.3
Their ability to train site staff in study protocol	6 15.8	-	-	-	5 55.6	1 33.3
Their ability to liaise with the study sponsor	6 15.8	-	-	-	3 33.3	3 100.0 E

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP BOX (5) CRA RATINGS
MATRIX, INC.

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Having low monitor turnover	6 15.8	1 16.7	1 10.0	1 10.0	2 22.2	1 33.3
Being innovative in their support of patient recruitment	3 7.9	-	-	-	3 33.3	-
CHI-SQUARE SIGNIFICANCE	<-----41.202-----> 14.1%*					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.
*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP 2 BOX (4 5) CRA RATINGS
 MATRIX, INC.

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
The quality of their CRAs over all	28 73.7	5 83.3	7 70.0	5 50.0	8 88.9 D	3 100.0 CD
Providing well designed case report forms	26 68.4	4 66.7	9 90.0 D	3 30.0	7 77.8 D	3 100.0 bD
Having an efficient data query handling process	26 68.4	5 83.3	7 70.0	5 50.0	6 66.7	3 100.0 CDE
Maintaining the availability of clinical trial supplies	23 60.5	5 83.3 C	4 40.0	5 50.0	6 66.7	3 100.0 CDE
Their grant payment process over all	23 60.5	-	8 80.0	7 70.0	5 55.6	3 100.0 DE
Support for facilitating regulatory approvals	22 57.9	4 66.7	8 80.0 D	3 30.0	5 55.6	2 66.7
Providing fair grant payment amounts	22 57.9	3 50.0	7 70.0	4 40.0	6 66.7	2 66.7
Managing monitor turnover	22 57.9	-	7 70.0	6 60.0	6 66.7	3 100.0 CDE
Providing prompt grant payments	21 55.3	2 33.3	7 70.0	4 40.0	5 55.6	3 100.0 BCDE
Having low monitor turnover	20 52.6	4 66.7	6 60.0	3 30.0	4 44.4	3 100.0 bCDE
Their ability to train site staff in study protocol	19 50.0	4 66.7 D	6 60.0 D	1 10.0	6 66.7 D	2 66.7 D
Providing reasonable grant payment schedules	18 47.4	1 16.7	6 60.0 B	6 60.0 B	3 33.3	2 66.7

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
MATRIX, INC.

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Their ability to liaise with the study sponsor	14 36.8	3 50.0	2 20.0	2 20.0	4 44.4	3 100.0 BCDE
Being innovative in their support of patient recruitment	8 21.1	-	2 20.0	1 10.0	5 55.6 cD	-
CHI-SQUARE SIGNIFICANCE	<-----32.845-----> 1.7%*					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.
*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Having low monitor turnover

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	20 52.6	4 66.7	6 60.0	3 30.0	4 44.4	3 100.0 bcDE
Excellent (5)	6 15.8	1 16.7	1 10.0	1 10.0	2 22.2	1 33.3
Good (4)	14 36.8	3 50.0	5 50.0	2 20.0	2 22.2	2 66.7
Three	11 28.9	1 16.7	2 20.0	6 60.0 BCe	2 22.2	-
NOT GOOD/POOR (1 2)	4 10.5	1 16.7	2 20.0	-	1 11.1	-
Two	4 10.5	1 16.7	2 20.0	-	1 11.1	-
Poor (1)	-	-	-	-	-	-
Don't know	3 7.9	-	-	1 10.0	2 22.2	-
CHI-SQUARE SIGNIFICANCE	<-----10.911-----> 46.3%*					
MEAN	3.6	3.7	3.5	3.4	3.7	4.3
STANDARD DEVIATION	0.9	1.0	1.0	0.7	1.1	0.6
STANDARD ERROR	0.2	0.4	0.3	0.2	0.4	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Managing monitor turnover

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	22 57.9	-	7 70.0	6 60.0	6 66.7	3 100.0 CDE
Excellent (5)	7 18.4	-	1 10.0	-	4 44.4 c	2 66.7 C
Good (4)	15 39.5	-	6 60.0 e	6 60.0 e	2 22.2	1 33.3
Three	11 28.9	5 83.3 CDE	2 20.0	2 20.0	2 22.2	-
NOT GOOD/POOR (1 2)	2 5.3	1 16.7	1 10.0	-	-	-
Two	1 2.6	1 16.7	-	-	-	-
Poor (1)	1 2.6	-	1 10.0	-	-	-
Don't know	3 7.9	-	-	2 20.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE	<-----30.057-----> 98.2%*					
MEAN	3.7	2.8	3.6	3.8	4.3	4.7
STANDARD DEVIATION	0.9	0.4	1.1	0.5	0.9	0.6
STANDARD ERROR	0.2	0.2	0.3	0.2	0.3	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Support for facilitating regulatory approvals

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	22 57.9	4 66.7	8 80.0 D	3 30.0	5 55.6	2 66.7
Excellent (5)	12 31.6	1 16.7	5 50.0 D	1 10.0	4 44.4 d	1 33.3
Good (4)	10 26.3	3 50.0 e	3 30.0	2 20.0	1 11.1	1 33.3
Three	7 18.4	1 16.7	2 20.0	3 30.0	1 11.1	-
NOT GOOD/POOR (1 2)	1 2.6	-	-	-	-	1 33.3
Two	-	-	-	-	-	-
Poor (1)	1 2.6	-	-	-	-	1 33.3
Don't know	8 21.1	1 16.7	-	4 40.0	3 33.3	-
CHI-SQUARE SIGNIFICANCE	<-----15.981-----> 80.8%*					
MEAN	4.1	4.0	4.3	3.7	4.5	3.3
STANDARD DEVIATION	1.0	0.7	0.8	0.8	0.8	2.1
STANDARD ERROR	0.2	0.3	0.3	0.3	0.3	1.2

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Maintaining the availability of clinical trial supplies

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	23 60.5	5 83.3 C	4 40.0	5 50.0	6 66.7	3 100.0 CDE
Excellent (5)	10 26.3	1 16.7	1 10.0	1 10.0	5 55.6 bcd	2 66.7 CD
Good (4)	13 34.2	4 66.7 E	3 30.0	4 40.0	1 11.1	1 33.3
Three	9 23.7	1 16.7	3 30.0	3 30.0	2 22.2	-
NOT GOOD/POOR (1 2)	1 2.6	-	-	1 10.0	-	-
Two	1 2.6	-	-	1 10.0	-	-
Poor (1)	-	-	-	-	-	-
Don't know	5 13.2	-	3 30.0	1 10.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE				<-----13.302-----> 65.3%*		
MEAN	4.0	4.0	3.7	3.6	4.4	4.7
STANDARD DEVIATION	0.8	0.6	0.8	0.9	0.9	0.6
STANDARD ERROR	0.1	0.3	0.3	0.3	0.3	0.3

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Being innovative in their support of patient recruitment

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	8 21.1	-	2 20.0	1 10.0	5 55.6 cD	-
Excellent (5)	3 7.9	-	-	-	3 33.3	-
Good (4)	5 13.2	-	2 20.0	1 10.0	2 22.2	-
Three	7 18.4	2 33.3	3 30.0	2 20.0	-	-
NOT GOOD/POOR (1 2)	14 36.8	2 33.3	4 40.0	5 50.0	2 22.2	1 33.3
Two	10 26.3	2 33.3	2 20.0	5 50.0 E	1 11.1	-
Poor (1)	4 10.5	-	2 20.0	-	1 11.1	1 33.3
Don't know	9 23.7	2 33.3	1 10.0	2 20.0	2 22.2	2 66.7 C
CHI-SQUARE SIGNIFICANCE	<-----25.576-----> 94.0%*					
MEAN	2.8	2.5	2.6	2.5	3.7	1.0
STANDARD DEVIATION	1.2	0.6	1.1	0.8	1.6	0.0
STANDARD ERROR	0.2	0.3	0.4	0.3	0.6	0.0

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Their ability to train site staff in study protocol

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	19 50.0	4 66.7 D	6 60.0 D	1 10.0	6 66.7 D	2 66.7 D
Excellent (5)	6 15.8	-	-	-	5 55.6	1 33.3
Good (4)	13 34.2	4 66.7 DE	6 60.0 DE	1 10.0	1 11.1	1 33.3
Three	11 28.9	1 16.7	2 20.0	6 60.0 BCE	1 11.1	1 33.3
NOT GOOD/POOR (1 2)	4 10.5	1 16.7	1 10.0	1 10.0	1 11.1	-
Two	3 7.9	1 16.7	-	1 10.0	1 11.1	-
Poor (1)	1 2.6	-	1 10.0	-	-	-
Don't know	4 10.5	-	1 10.0	2 20.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE	<-----30.273-----> 98.3%*					
MEAN	3.6	3.5	3.4	3.0	4.3	4.0
STANDARD DEVIATION	1.0	0.8	1.0	0.5	1.2	1.0
STANDARD ERROR	0.2	0.3	0.3	0.2	0.4	0.6

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Their ability to liaise with the study sponsor

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	14 36.8	3 50.0	2 20.0	2 20.0	4 44.4	3 100.0 BCDE
Excellent (5)	6 15.8	-	-	-	3 33.3	3 100.0 E
Good (4)	8 21.1	3 50.0 e	2 20.0	2 20.0	1 11.1	-
Three	10 26.3	1 16.7	3 30.0	5 50.0 E	1 11.1	-
NOT GOOD/POOR (1 2)	5 13.2	1 16.7	3 30.0	1 10.0	-	-
Two	4 10.5	1 16.7	2 20.0	1 10.0	-	-
Poor (1)	1 2.6	-	1 10.0	-	-	-
Don't know	9 23.7	1 16.7	2 20.0	2 20.0	4 44.4	-
CHI-SQUARE SIGNIFICANCE	<-----28.166-----> 97.0%*					
MEAN	3.5	3.4	2.8	3.1	4.4	5.0
STANDARD DEVIATION	1.1	0.9	1.0	0.6	0.9	0.0
STANDARD ERROR	0.2	0.4	0.4	0.2	0.4	0.0

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 The quality of their CRAs over all

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	28 73.7	5 83.3	7 70.0	5 50.0	8 88.9 D	3 100.0 CD
Excellent (5)	10 26.3	1 16.7	2 20.0	-	6 66.7 BC	1 33.3
Good (4)	18 47.4	4 66.7 e	5 50.0	5 50.0	2 22.2	2 66.7
Three	7 18.4	-	2 20.0	4 40.0	1 11.1	-
NOT GOOD/POOR (1 2)	2 5.3	1 16.7	1 10.0	-	-	-
Two	1 2.6	1 16.7	-	-	-	-
Poor (1)	1 2.6	-	1 10.0	-	-	-
Don't know	1 2.6	-	-	1 10.0	-	-
CHI-SQUARE SIGNIFICANCE	<-----23.08-----> 88.8%*					
MEAN	3.9	3.8 BA	3.7 B	3.6 B	4.6 A	4.3 BA
STANDARD DEVIATION	0.9	1.0	1.2	0.5	0.7	0.6
STANDARD ERROR	0.1	0.4	0.4	0.2	0.2	0.3

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Providing well designed case report forms

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	26 68.4	4 66.7	9 90.0 D	3 30.0	7 77.8 D	3 100.0 bD
Excellent (5)	7 18.4	2 33.3	-	-	2 22.2	3 100.0 BE
Good (4)	19 50.0	2 33.3	9 90.0 BDe	3 30.0	5 55.6	-
Three	8 21.1	-	1 10.0	5 50.0 C	2 22.2	-
NOT GOOD/POOR (1 2)	3 7.9	2 33.3	-	1 10.0	-	-
Two	3 7.9	2 33.3	-	1 10.0	-	-
Poor (1)	-	-	-	-	-	-
Don't know	1 2.6	-	-	1 10.0	-	-
CHI-SQUARE SIGNIFICANCE	<-----34.117-----> 99.9%*					
MEAN	3.8	3.7 CB	3.9 CB	3.2 C	4.0 BA	5.0 A
STANDARD DEVIATION	0.8	1.4	0.3	0.7	0.7	0.0
STANDARD ERROR	0.1	0.6	0.1	0.2	0.2	0.0

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Having an efficient data query handling process

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	26 68.4	5 83.3	7 70.0	5 50.0	6 66.7	3 100.0 CDE
Excellent (5)	10 26.3	1 16.7	2 20.0	-	4 44.4	3 100.0 BCE
Good (4)	16 42.1	4 66.7 e	5 50.0	5 50.0	2 22.2	-
Three	8 21.1	1 16.7	2 20.0	4 40.0	1 11.1	-
NOT GOOD/POOR (1 2)	2 5.3	-	1 10.0	-	1 11.1	-
Two	2 5.3	-	1 10.0	-	1 11.1	-
Poor (1)	-	-	-	-	-	-
Don't know	2 5.3	-	-	1 10.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE	<-----18.202-----> 89.0%*					
MEAN	3.9	4.0 BA	3.8 B	3.6 B	4.1 BA	5.0 A
STANDARD DEVIATION	0.9	0.6	0.9	0.5	1.1	0.0
STANDARD ERROR	0.1	0.3	0.3	0.2	0.4	0.0

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Providing fair grant payment amounts

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	22 57.9	3 50.0	7 70.0	4 40.0	6 66.7	2 66.7
Excellent (5)	7 18.4	-	1 10.0	1 10.0	4 44.4 cd	1 33.3
Good (4)	15 39.5	3 50.0	6 60.0 e	3 30.0	2 22.2	1 33.3
Three	11 28.9	2 33.3	2 20.0	4 40.0	2 22.2	1 33.3
NOT GOOD/POOR (1 2)	1 2.6	-	1 10.0	-	-	-
Two	1 2.6	-	1 10.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	4 10.5	1 16.7	-	2 20.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE	<-----10.972-----> 46.9%*					
MEAN	3.8	3.6	3.7	3.6	4.3	4.0
STANDARD DEVIATION	0.8	0.5	0.8	0.7	0.9	1.0
STANDARD ERROR	0.1	0.2	0.3	0.3	0.3	0.6

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Providing reasonable grant payment schedules

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	18 47.4	1 16.7	6 60.0 B	6 60.0 B	3 33.3	2 66.7
Excellent (5)	8 21.1	-	2 20.0	1 10.0	3 33.3	2 66.7 D
Good (4)	10 26.3	1 16.7	4 40.0	5 50.0	-	-
Three	15 39.5	3 50.0	3 30.0	3 30.0	5 55.6	1 33.3
NOT GOOD/POOR (1 2)	1 2.6	1 16.7	-	-	-	-
Two	-	-	-	-	-	-
Poor (1)	1 2.6	1 16.7	-	-	-	-
Don't know	4 10.5	1 16.7	1 10.0	1 10.0	1 11.1	-
CHI-SQUARE SIGNIFICANCE	<-----18.23-----> 89.1%*					
MEAN	3.7	2.8	3.9	3.8	3.8	4.3
STANDARD DEVIATION	0.9	1.1	0.8	0.7	1.0	1.2
STANDARD ERROR	0.2	0.5	0.3	0.2	0.4	0.7

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Providing prompt grant payments

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	21 55.3	2 33.3	7 70.0	4 40.0	5 55.6	3 100.0 BCDE
Excellent (5)	8 21.1	-	1 10.0	-	4 44.4 c	3 100.0 CE
Good (4)	13 34.2	2 33.3	6 60.0 E	4 40.0	1 11.1	-
Three	9 23.7	3 50.0 e	2 20.0	3 30.0	1 11.1	-
NOT GOOD/POOR (1 2)	5 13.2	1 16.7	1 10.0	2 20.0	1 11.1	-
Two	4 10.5	-	1 10.0	2 20.0	1 11.1	-
Poor (1)	1 2.6	1 16.7	-	-	-	-
Don't know	3 7.9	-	-	1 10.0	2 22.2	-
CHI-SQUARE SIGNIFICANCE	<-----28.901-----> 97.5%*					
MEAN	3.7	3.0	3.7	3.2	4.1	5.0
STANDARD DEVIATION	1.1	1.1	0.8	0.8	1.2	0.0
STANDARD ERROR	0.2	0.4	0.3	0.3	0.5	0.0

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MATRIX, INC. RATING
 Their grant payment process over all

FILTER: RATED MATRIX, INC.

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	38 100.0	6 100.0	10 100.0	10 100.0	9 100.0	3 100.0
EXCELLENT/GOOD (4 5)	23 60.5	-	8 80.0	7 70.0	5 55.6	3 100.0 DE
Excellent (5)	9 23.7	-	3 30.0	1 10.0	4 44.4 d	1 33.3
Good (4)	14 36.8	-	5 50.0 E	6 60.0 E	1 11.1	2 66.7 e
Three	10 26.3	4 66.7 CDe	2 20.0	2 20.0	2 22.2	-
NOT GOOD/POOR (1 2)	1 2.6	1 16.7	-	-	-	-
Two	-	-	-	-	-	-
Poor (1)	1 2.6	1 16.7	-	-	-	-
Don't know	4 10.5	1 16.7	-	1 10.0	2 22.2	-
CHI-SQUARE SIGNIFICANCE	<-----21.579-----> 95.7%*					
MEAN	3.9	2.6	4.1	3.9	4.3	4.3
STANDARD DEVIATION	0.9	0.9	0.7	0.6	1.0	0.6
STANDARD ERROR	0.2	0.4	0.2	0.2	0.4	0.3

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 MEAN SUMMARY CRA RATINGS
 PHARMA FOCUS

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17	10	5	1	1	-
	100.0	100.0	100.0	100.0	100.0	
Support for facilitating regulatory approvals	4.3	4.4	4.2	4.0	4.0	-
Their grant payment process over all	4.1	3.9	4.0	5.0	5.0	-
Maintaining the availability of clinical trial supplies	4.1	4.2	3.3	5.0	5.0	-
The quality of their CRAs over all	3.9	4.0	3.4	5.0	5.0	-
Providing fair grant payment amounts	3.9	3.8	3.8	5.0	5.0	-
Their ability to train site staff in study protocol	3.9	4.2	3.6	4.0	3.0	-
Their ability to liaise with the study sponsor	3.9	3.9	3.3	5.0	5.0	-
Providing prompt grant payments	3.8	3.9	3.4	4.0	5.0	-
Having low monitor turnover	3.8	3.8	3.4	5.0	5.0	-
Managing monitor turnover	3.8	3.9	2.8	5.0	5.0	-
Having an efficient data query handling process	3.7	3.6	3.6	4.0	5.0	-
Providing well designed case report forms	3.7	3.7	3.6	4.0	4.0	-
Providing reasonable grant payment schedules	3.7	3.4	3.8	4.0	5.0	-
Being innovative in their support of patient recruitment	3.3	3.6	1.7	3.0	5.0	-
CHI-SQUARE SIGNIFICANCE	<-----1.824-----> .0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP BOX (5) CRA RATINGS
 PHARMA FOCUS

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
Support for facilitating regulatory approvals	8 47.1	5 50.0	3 60.0	-	-	-
Managing monitor turnover	7 41.2	4 40.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Maintaining the availability of clinical trial supplies	7 41.2	4 40.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Their ability to train site staff in study protocol	7 41.2	5 50.0	2 40.0	-	-	-
Having low monitor turnover	6 35.3	3 30.0	1 20.0	1 100.0 BC	1 100.0 BC	-
The quality of their CRAs over all	6 35.3	3 30.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Providing fair grant payment amounts	5 29.4	1 10.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Providing prompt grant payments	5 29.4	2 20.0	2 40.0	-	1 100.0 BC	-
Their grant payment process over all	5 29.4	1 10.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Having an efficient data query handling process	4 23.5	2 20.0	1 20.0	-	1 100.0 BC	-
Their ability to liaise with the study sponsor	4 23.5	2 20.0	-	1 100.0 B	1 100.0 B	-
Providing reasonable grant payment schedules	3 17.6	1 10.0	1 20.0	-	1 100.0 BC	-

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP BOX (5) CRA RATINGS
PHARMA FOCUS

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Providing well designed case report forms	2 11.8	1 10.0	1 20.0	-	-	-
Being innovative in their support of patient recruitment	2 11.8	1 10.0	-	-	1 100.0 B	-
CHI-SQUARE SIGNIFICANCE	<-----19.359-----> .4%*					

Comparison Groups: BCDEF
Oneway ANOVA for Means
Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
Independent Z-Test for Percentages
Upper case letters indicate significance at the 95% level.
Lower case letters indicate significance at the 90% level.
*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 TOP 2 BOX (4 5) CRA RATINGS
 PHARMA FOCUS

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
Support for facilitating regulatory approvals	13 76.5	7 70.0	4 80.0	1 100.0 B	1 100.0 B	-
Maintaining the availability of clinical trial supplies	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Their ability to liaise with the study sponsor	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
The quality of their CRAs over all	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Providing fair grant payment amounts	12 70.6	7 70.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Their grant payment process over all	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Providing well designed case report forms	11 64.7	7 70.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Having low monitor turnover	11 64.7	6 60.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Providing prompt grant payments	11 64.7	7 70.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Their ability to train site staff in study protocol	11 64.7	7 70.0	3 60.0	1 100.0 Bc	-	-
Having an efficient data query handling process	10 58.8	5 50.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Managing monitor turnover	10 58.8	7 70.0 C	1 20.0	1 100.0 BC	1 100.0	-

BCComparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
TOP 2 BOX (4 5) CRA RATINGS
PHARMA FOCUS

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
Being innovative in their support of patient recruitment	8 47.1	7 70.0	-	-	1 100.0 B	-
Providing reasonable grant payment schedules	8 47.1	4 40.0	2 40.0	1 100.0 BC	1 100.0 BC	-
CHI-SQUARE SIGNIFICANCE	<-----8.427-----> .0%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Having low monitor turnover

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	11 64.7	6 60.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Excellent (5)	6 35.3	3 30.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Good (4)	5 29.4	3 30.0	2 40.0	-	-	-
Three	2 11.8	1 10.0	1 20.0	-	-	-
NOT GOOD/POOR (1 2)	3 17.6	2 20.0	1 20.0	-	-	-
Two	2 11.8	2 20.0	-	-	-	-
Poor (1)	1 5.9	-	1 20.0	-	-	-
Don't know	1 5.9	1 10.0	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----7.538-----> 18.0%*					
MEAN	3.8	3.8	3.4	5.0	5.0	
STANDARD DEVIATION	1.3	1.2	1.5	0.0	0.0	
STANDARD ERROR	0.3	0.4	0.7	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Managing monitor turnover

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	10 58.8	7 70.0	1 20.0	1 100.0	1 100.0	-
		C		BC	BC	
Excellent (5)	7 41.2	4 40.0	1 20.0	1 100.0	1 100.0	-
				BC	BC	
Good (4)	3 17.6	3 30.0	-	-	-	-
Three	2 11.8	1 10.0	1 20.0	-	-	-
NOT GOOD/POOR (1 2)	4 23.5	2 20.0	2 40.0	-	-	-
Two	3 17.6	2 20.0	1 20.0	-	-	-
Poor (1)	1 5.9	-	1 20.0	-	-	-
Don't know	1 5.9	-	1 20.0	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----7.867-----> 20.5%*					
MEAN	3.8	3.9	2.8	5.0	5.0	
STANDARD DEVIATION	1.4	1.2	1.7	0.0	0.0	
STANDARD ERROR	0.3	0.4	0.9	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Support for facilitating regulatory approvals

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	13 76.5	7 70.0	4 80.0	1 100.0 B	1 100.0 B	-
Excellent (5)	8 47.1	5 50.0	3 60.0	-	-	-
Good (4)	5 29.4	2 20.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Three	-	-	-	-	-	-
NOT GOOD/POOR (1 2)	2 11.8	1 10.0	1 20.0	-	-	-
Two	2 11.8	1 10.0	1 20.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	2 11.8	2 20.0	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----4.772-----> 42.7%*					
MEAN	4.3	4.4	4.2	4.0	4.0	
STANDARD DEVIATION	1.0	1.1	1.3	0.0	0.0	
STANDARD ERROR	0.3	0.4	0.6	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Maintaining the availability of clinical trial supplies

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17	10	5	1	1	-
	100.0	100.0	100.0	100.0	100.0	
EXCELLENT/GOOD (4 5)	12	8	2	1	1	-
	70.6	80.0	40.0	100.0	100.0	
				C	C	
Excellent (5)	7	4	1	1	1	-
	41.2	40.0	20.0	100.0	100.0	
				BC	BC	
Good (4)	5	4	1	-	-	-
	29.4	40.0	20.0			
Three	3	2	1	-	-	-
	17.6	20.0	20.0			
NOT GOOD/POOR (1 2)	1	-	1	-	-	-
	5.9		20.0			
Two	-	-	-	-	-	-
Poor (1)	1	-	1	-	-	-
	5.9		20.0			
Don't know	1	-	1	-	-	-
	5.9		20.0			
CHI-SQUARE SIGNIFICANCE	<-----6.187----->					
	27.9%*					
MEAN	4.1	4.2	3.3	5.0	5.0	
STANDARD DEVIATION	1.1	0.8	1.7	0.0	0.0	
STANDARD ERROR	0.3	0.2	0.9	0.0	0.0	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Being innovative in their support of patient recruitment

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17	10	5	1	1	-
	100.0	100.0	100.0	100.0	100.0	
EXCELLENT/GOOD (4 5)	8	7	-	-	1	-
	47.1	70.0			100.0	
					B	
Excellent (5)	2	1	-	-	1	-
	11.8	10.0			100.0	
					B	
Good (4)	6	6	-	-	-	-
	35.3	60.0				
Three	3	2	-	1	-	-
	17.6	20.0		100.0		
				B		
NOT GOOD/POOR (1 2)	4	1	3	-	-	-
	23.5	10.0	60.0			
			B			
Two	2	-	2	-	-	-
	11.8		40.0			
Poor (1)	2	1	1	-	-	-
	11.8	10.0	20.0			
Don't know	2	-	2	-	-	-
	11.8		40.0			
CHI-SQUARE SIGNIFICANCE	<-----22.5----->					
	96.8%*					
MEAN	3.3	3.6	1.7	3.0	5.0	
STANDARD DEVIATION	1.3	1.1	0.6	0.0	0.0	
STANDARD ERROR	0.3	0.3	0.3	0.0	0.0	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2010
PHARMA FOCUS RATING
Their ability to train site staff in study protocol

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	11 64.7	7 70.0	3 60.0	1 100.0	-	-
Excellent (5)	7 41.2	5 50.0	2 40.0	-	-	-
Good (4)	4 23.5	2 20.0	1 20.0	1 100.0	-	-
Three	2 11.8	1 10.0	-	-	1 100.0	-
NOT GOOD/POOR (1 2)	3 17.6	1 10.0	2 40.0	-	-	-
Two	3 17.6	1 10.0	2 40.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	1 5.9	1 10.0	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----12.504-----> 81.4%*					
MEAN	3.9	4.2	3.6	4.0	3.0	
STANDARD DEVIATION	1.2	1.1	1.5	0.0	0.0	
STANDARD ERROR	0.3	0.4	0.7	0.0	0.0	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Their ability to liaise with the study sponsor

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Excellent (5)	4 23.5	2 20.0	-	1 100.0 B	1 100.0 B	-
Good (4)	8 47.1	6 60.0	2 40.0	-	-	-
Three	1 5.9	1 10.0	-	-	-	-
NOT GOOD/POOR (1 2)	2 11.8	1 10.0	1 20.0	-	-	-
Two	2 11.8	1 10.0	1 20.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	2 11.8	-	2 40.0	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----8-----> 46.6%*					
MEAN	3.9	3.9	3.3	5.0	5.0	
STANDARD DEVIATION	1.0	0.9	1.2	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.7	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 The quality of their CRAs over all

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Excellent (5)	6 35.3	3 30.0	1 20.0	1 100.0 BC	1 100.0 BC	-
Good (4)	6 35.3	5 50.0	1 20.0	-	-	-
Three	3 17.6	1 10.0	2 40.0	-	-	-
NOT GOOD/POOR (1 2)	2 11.8	1 10.0	1 20.0	-	-	-
Two	2 11.8	1 10.0	1 20.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	-	-	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----7.083-----> 37.2%*					
MEAN	3.9	4.0	3.4	5.0	5.0	
STANDARD DEVIATION	1.0	0.9	1.1	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.5	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Providing well designed case report forms

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	11 64.7	7 70.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Excellent (5)	2 11.8	1 10.0	1 20.0	-	-	-
Good (4)	9 52.9	6 60.0 c	1 20.0	1 100.0 BC	1 100.0 BC	-
Three	5 29.4	2 20.0	3 60.0	-	-	-
NOT GOOD/POOR (1 2)	1 5.9	1 10.0	-	-	-	-
Two	1 5.9	1 10.0	-	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	-	-	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----5.686-----> 22.9%*					
MEAN	3.7	3.7	3.6	4.0	4.0	
STANDARD DEVIATION	0.8	0.8	0.9	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.4	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Having an efficient data query handling process

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	10 58.8	5 50.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Excellent (5)	4 23.5	2 20.0	1 20.0	-	1 100.0 BC	-
Good (4)	6 35.3	3 30.0	2 40.0	1 100.0 BC	-	-
Three	5 29.4	4 40.0	1 20.0	-	-	-
NOT GOOD/POOR (1 2)	2 11.8	1 10.0	1 20.0	-	-	-
Two	2 11.8	1 10.0	1 20.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	-	-	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----6.12-----> 27.2%*					
MEAN	3.7	3.6	3.6	4.0	5.0	
STANDARD DEVIATION	1.0	1.0	1.1	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.5	0.0	0.0	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Providing fair grant payment amounts

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	12 70.6	7 70.0	3 60.0	1 100.0 Bc	1 100.0 Bc	-
Excellent (5)	5 29.4	1 10.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Good (4)	7 41.2	6 60.0 c	1 20.0	-	-	-
Three	2 11.8	1 10.0	1 20.0	-	-	-
NOT GOOD/POOR (1 2)	2 11.8	1 10.0	1 20.0	-	-	-
Two	2 11.8	1 10.0	1 20.0	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	1 5.9	1 10.0	-	-	-	-
CHI-SQUARE SIGNIFICANCE				<-----7.893-----> 45.5%*		
MEAN	3.9	3.8	3.8	5.0	5.0	
STANDARD DEVIATION	1.0	0.8	1.3	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.6	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Providing reasonable grant payment schedules

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	8 47.1	4 40.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Excellent (5)	3 17.6	1 10.0	1 20.0	-	1 100.0 BC	-
Good (4)	5 29.4	3 30.0	1 20.0	1 100.0 BC	-	-
Three	6 35.3	4 40.0	2 40.0	-	-	-
NOT GOOD/POOR (1 2)	1 5.9	1 10.0	-	-	-	-
Two	1 5.9	1 10.0	-	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	2 11.8	1 10.0	1 20.0	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----7.167-----> 38.0%*					
MEAN	3.7	3.4	3.8	4.0	5.0	
STANDARD DEVIATION	0.9	0.9	1.0	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.5	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Providing prompt grant payments

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17	10	5	1	1	-
	100.0	100.0	100.0	100.0	100.0	
EXCELLENT/GOOD (4 5)	11	7	2	1	1	-
	64.7	70.0	40.0	100.0	100.0	
				BC	BC	
Excellent (5)	5	2	2	-	1	-
	29.4	20.0	40.0		100.0	
					BC	
Good (4)	6	5	-	1	-	-
	35.3	50.0		100.0		
				B		
Three	2	1	1	-	-	-
	11.8	10.0	20.0			
NOT GOOD/POOR (1 2)	3	1	2	-	-	-
	17.6	10.0	40.0			
Two	3	1	2	-	-	-
	17.6	10.0	40.0			
Poor (1)	-	-	-	-	-	-
Don't know	1	1	-	-	-	-
	5.9	10.0				
CHI-SQUARE SIGNIFICANCE				<-----8.604-----> 52.5%*		
MEAN	3.8	3.9	3.4	4.0	5.0	
STANDARD DEVIATION	1.1	0.9	1.5	0.0	0.0	
STANDARD ERROR	0.3	0.3	0.7	0.0	0.0	

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2010
 PHARMA FOCUS RATING
 Their grant payment process over all

FILTER: RATED PHARMA FOCUS

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	17 100.0	10 100.0	5 100.0	1 100.0	1 100.0	-
EXCELLENT/GOOD (4 5)	12 70.6	8 80.0	2 40.0	1 100.0 C	1 100.0 C	-
Excellent (5)	5 29.4	1 10.0	2 40.0	1 100.0 BC	1 100.0 BC	-
Good (4)	7 41.2	7 70.0	-	-	-	-
Three	2 11.8	-	2 40.0	-	-	-
NOT GOOD/POOR (1 2)	1 5.9	1 10.0	-	-	-	-
Two	1 5.9	1 10.0	-	-	-	-
Poor (1)	-	-	-	-	-	-
Don't know	2 11.8	1 10.0	1 20.0	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----15.167-----> 91.4%*					
MEAN	4.1	3.9	4.0	5.0	5.0	
STANDARD DEVIATION	0.9	0.8	1.2	0.0	0.0	
STANDARD ERROR	0.2	0.3	0.6	0.0	0.0	

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2020
 HOW MANY YEARS OF EXPERIENCE DO YOU HAVE CONDUCTING CLINICAL TRIALS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
Under 5	21 11.3	4 10.0	4 10.8	4 6.6	3 12.5	6 25.0 D
5-7	41 22.0	7 17.5	8 21.6	14 23.0	6 25.0	6 25.0
8-10	44 23.7	7 17.5	7 18.9	21 34.4 Bce	4 16.7	5 20.8
11-15	38 20.4	11 27.5 E	10 27.0 E	12 19.7	2 8.3	3 12.5
More than 15	40 21.5	10 25.0	8 21.6	9 14.8	9 37.5 Df	4 16.7
Mean	11.4	11.8 A	11.8 A	11.1 A	11.8 A	10.2 A
Standard Deviation	6.7	5.7	6.7	5.5	7.3	9.8
Standard Error	0.5	0.9	1.1	0.7	1.5	2.0
No answer	2 1.1	1 2.5	-	1 1.6	-	-
CHI-SQUARE SIGNIFICANCE	<-----19.253-----> 11.0%					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2030
HOW MANY CLINICAL TRIALS HAVE YOU WORKED ON IN THE LAST 24 MONTHS

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
Under 5	87 46.8	13 32.5	20 54.1 b	33 54.1 B	10 41.7	11 45.8
5-7	37 19.9	8 20.0	8 21.6	7 11.5	4 16.7	10 41.7 bcDE
8-10	37 19.9	9 22.5	7 18.9	14 23.0 f	5 20.8	2 8.3
11-15	13 7.0	5 12.5	-	5 8.2	2 8.3	1 4.2
More than 15	10 5.4	4 10.0 d	2 5.4	1 1.6	3 12.5	-
Mean	7.3	9.5 BA	6.2 B	6.0 B	11.3 A	4.6 B
Standard Deviation	9.9	11.2	5.8	5.0	20.1	3.1
Standard Error	0.7	1.8	0.9	0.6	4.1	0.6
No answer	2 1.1	1 2.5	-	1 1.6	-	-
CHI-SQUARE SIGNIFICANCE	<-----24.582-----> 35.0%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2040
 WITH WHICH CRO DO YOU MOST PREFER TO WORK

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
CROPHARMA	64 34.4	3 7.5	13 35.1 B	17 27.9 B	12 50.0 Bd	19 79.2 BCDE
BETA THERAPEUTIC	8 4.3	1 2.5	2 5.4	5 8.2	-	-
PHARMA FOCUS	7 3.8	5 12.5 D	-	1 1.6	1 4.2	-
MATRIX, INC.	4 2.2	-	1 2.7	-	2 8.3	1 4.2
Other	29 15.6	13 32.5 CD	3 8.1	7 11.5	6 25.0 c	-
No preference	73 39.2	18 45.0 EF	18 48.6 EF	31 50.8 EF	3 12.5	3 12.5
No answer	1 0.5	-	-	-	-	1 4.2
CHI-SQUARE SIGNIFICANCE	<-----74.623-----> 100.0%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means
 Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages
 Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.
 *** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2050
 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE MOST?

FILTER: HAVE A PREFERRED CRA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	112 100.0	22 100.0	19 100.0	30 100.0	21 100.0	20 100.0
Efficient/Professional	23 20.5	6 27.3	3 15.8	6 20.0	2 9.5	6 30.0 e
Staff/Well trained/competent/polite/ motivated	22 19.6	3 13.6	8 42.1 BEF	6 20.0	3 14.3	2 10.0
Know them/Have experience using them	21 18.8	3 13.6	2 10.5	5 16.7	5 23.8	6 30.0
Good quality work/Reliable	15 13.4	3 13.6	3 15.8	6 20.0	3 14.3	-
Good communications/quick response	11 9.8	1 4.5	1 5.3	3 10.0	5 23.8 bcf	1 5.0
Well-organized	9 8.0	3 13.6	1 5.3	4 13.3	1 4.8	-
Easy to work with/not a lot of staff turnover	2 1.8	1 4.5	-	-	-	1 5.0
Good case files	1 0.9	1 4.5	-	-	-	-
Other	3 2.7	1 4.5	1 5.3	-	-	1 5.0
No particular reason	4 3.6	-	-	-	1 4.8	3 15.0
No answer	1 0.9	-	-	-	1 4.8	-
CHI-SQUARE SIGNIFICANCE	<-----45.286-----> 86.2%*					

Comparison Groups: BCDEF
 Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.
 Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.
 Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2050
WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE MOST?

FILTER: PREFER CROPHARMA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	64 100.0	3 100.0	13 100.0	17 100.0	12 100.0	19 100.0
Know them/Have experience using them	14 21.9	-	2 15.4	4 23.5	3 25.0	5 26.3
Staff/Well trained/competent/polite/ motivated	13 20.3	-	5 38.5 f	4 23.5	2 16.7	2 10.5
Efficient/Professional	11 17.2	-	1 7.7	3 17.6	1 8.3	6 31.6 ce
Good communications/quick response	6 9.4	-	-	1 5.9	4 33.3 df	1 5.3
Well-organized	6 9.4	2 66.7 Cd	1 7.7	3 17.6	-	-
Good quality work/Reliable	5 7.8	-	3 23.1	2 11.8	-	-
Good case files	1 1.6	1 33.3	-	-	-	-
Easy to work with/not a lot of staff turnover	1 1.6	-	-	-	-	1 5.3
Other	2 3.1	-	1 7.7	-	-	1 5.3
No particular reason	4 6.3	-	-	-	1 8.3	3 15.8
No answer	1 1.6	-	-	-	1 8.3	-
CHI-SQUARE SIGNIFICANCE	<-----69.517-----> 99.9%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2050
 WITH WHICH CRO DO YOU LEAST PREFER TO WORK

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
CROPHARMA	11 5.9	4 10.0	2 5.4	4 6.6	1 4.2	-
BETA THERAPEUTIC	5 2.7	3 7.5	-	2 3.3	-	-
MATRIX, INC.	4 2.2	-	1 2.7	2 3.3	1 4.2	-
PHARMA FOCUS	1 0.5	-	1 2.7	-	-	-
Other	13 7.0	8 20.0 D	-	2 3.3	3 12.5	-
No preference	144 77.4	24 60.0	31 83.8 B	51 83.6 B	19 79.2 b	19 79.2 b
No answer	8 4.3	1 2.5	2 5.4	-	-	5 20.8
CHI-SQUARE SIGNIFICANCE	<-----32.57-----> 96.2%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2050
 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE LEAST?

FILTER: HAVE A LEAST PREFERRED CRA

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	34 100.0	15 100.0	4 100.0	10 100.0	5 100.0	-
Not organized	9 26.5	5 33.3	-	2 20.0	2 40.0	-
Not efficient/bad protocol/ communications	7 20.6	4 26.7	2 50.0	1 10.0	-	-
Staff poorly trained	5 14.7	1 6.7	1 25.0	2 20.0	1 20.0	-
Staff turnover	4 11.8	2 13.3	-	2 20.0	-	-
Do not understand study	4 11.8	-	-	2 20.0	2 40.0	-
Money/bankrupt/owe money/not efficient payments	2 5.9	1 6.7	-	1 10.0	-	-
Other	3 8.8	2 13.3	1 25.0	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----18.142-----> 55.4%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

*** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2050
 WHY DO YOU MOST PREFER TO WORK WITH [CRA] THE LEAST?

FILTER: CROPHARMA LEAST PREFERRED

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	11 100.0	4 100.0	2 100.0	4 100.0	1 100.0	-
Not efficient/bad protocol/ communications	3 27.3	2 50.0	1 50.0	-	-	-
Staff turnover	2 18.2	-	-	2 50.0	-	-
Do not understand study	2 18.2	-	-	1 25.0	1 100.0 D	-
Staff poorly trained	1 9.1	-	1 50.0	-	-	-
Not organized	1 9.1	-	-	1 25.0	-	-
Other	2 18.2	2 50.0	-	-	-	-
CHI-SQUARE SIGNIFICANCE	<-----20.625-----> 85.1%*					

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
 PHARMACEUTICAL MARKET RESEARCH COMPANY
 NOVEMBER 2007

QUESTION 2080
 OVER ALL, HOW WOULD YOU RATE THE QUALITY OF YOUR WORKING RELATIONSHIP WITH
 CROPHARMA

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
EXCELLENT/GOOD (4 5)	142 76.3	24 60.0	27 73.0	45 73.8	22 BCD	24 BCD
Excellent (5)	50 26.9	6 15.0	5 13.5	10 16.4	13 BCD	16 BCD
Good (4)	92 49.5	18 45.0	22 59.5 eF	35 57.4 eF	9 37.5	8 33.3
Three	35 18.8	12 30.0 E	8 21.6 E	14 23.0 E	1 4.2	-
NOT GOOD/POOR (1 2)	7 3.8	3 7.5	2 5.4	1 1.6	1 4.2	-
Two	5 2.7	2 5.0	1 2.7	1 1.6	1 4.2	-
Poor (1)	2 1.1	1 2.5	1 2.7	-	-	-
Don't know	1 0.5	1 2.5	-	-	-	-
No answer	1 0.5	-	-	1 1.6	-	-
CHI-SQUARE SIGNIFICANCE	<-----46.536-----> 100.0%*					
MEAN	4.0	3.7 B	3.8 B	3.9 B	4.4 A	4.7 A
STANDARD DEVIATION	0.8	0.9	0.8	0.7	0.8	0.5
STANDARD ERROR	0.1	0.1	0.1	0.1	0.2	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.

CROPHARMA, INC. INVESTIGATOR STUDY
PHARMACEUTICAL MARKET RESEARCH COMPANY
NOVEMBER 2007

QUESTION 2090
HOW LIKELY WOULD YOU BE TO RECOMMEND CROPHARMA

TOTAL

	<----- COUNTRY ----->					
	TOTAL	UK	Germany	France	Ireland	Spain
	(A)	(B)	(C)	(D)	(E)	(F)
TOTAL	186 100.0	40 100.0	37 100.0	61 100.0	24 100.0	24 100.0
EXTREMELY/VERY LIKELY (4 5)	129 69.4	20 50.0	27 73.0 B	38 62.3	21 87.5 BD	23 95.8 BCD
Extremely likely (5)	57 30.6	8 20.0	6 16.2	9 14.8	16 66.7 BCD	18 75.0 BCD
Very likely (4)	72 38.7	12 30.0	21 56.8 BEF	29 47.5 bEF	5 20.8	5 20.8
Three	45 24.2	14 35.0 EF	8 21.6 F	20 32.8 EF	2 8.3	1 4.2
VERY UNLIKELY/UNLIKELY (1 2)	11 5.9	6 15.0 d	2 5.4	2 3.3	1 4.2	-
Unlikely (2)	7 3.8	4 10.0 d	1 2.7	1 1.6	1 4.2	-
Very unlikely(1)	4 2.2	2 5.0	1 2.7	1 1.6	-	-
No answer	1 0.5	-	-	1 1.6	-	-
CHI-SQUARE SIGNIFICANCE	<-----62.404-----> 100.0%*					
MEAN	3.9	3.5 B	3.8 B	3.7 B	4.5 A	4.7 A
STANDARD DEVIATION	0.9	1.1	0.8	0.8	0.8	0.6
STANDARD ERROR	0.1	0.2	0.1	0.1	0.2	0.1

Comparison Groups: BCDEF

Oneway ANOVA for Means

Homogenous groups are represented by the same letter and are significantly different from other groups at the 95% level.

Independent Z-Test for Percentages

Upper case letters indicate significance at the 95% level.

Lower case letters indicate significance at the 90% level.

** Denotes Chi-Square where at least one cell has an expected value of less than 1 or more than 20% of the cells have an expected value of less than 5.